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GuidelineSummary Bacterial meningitis and meningococcal sepsis are rare conditions with high case
fatality rates. Early recognition and prompt treatment saves lives. In 1999 the British Infection
Society produced a consensus statement for the management of immunocompetent adults
with meningitis and meningococcal sepsis.
Since 1999 there have been many changes. We therefore set out to produce revised guide-
lines which provide a standardised evidence-based approach to the management of acute com-
munity acquired meningitis and meningococcal sepsis in adults.
A working party consisting of infectious diseases physicians, neurologists, acute physicians,
intensivists, microbiologists, public health experts and patient group representatives was
formed. Key questions were identified and the literature reviewed. All recommendations were
graded and agreed upon by the working party. The guidelines, which for the first time include
viral meningitis, are written in accordance with the AGREE 2 tool and recommendations graded
according to the GRADE system.
Main changes from the original statement include the indications for pre-hospital antibi-
otics, timing of the lumbar puncture and the indications for neuroimaging. The list of investi-
gations has been updated and more emphasis is placed on molecular diagnosis. Approaches to
both antibiotic and steroid therapy have been revised. Several recommendations have been
given regarding the follow-up of patients.
ª 2016 The Authors. Published by Elsevier Ltd on behalf of the The British Infection
Association. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Although bacterial meningitis and meningococcal sepsis are
rare in adults and the average UK NHS district general
hospital will see ten or fewer laboratory confirmed cases
per year, they continue to carry a high morbidity and
mortality. Delays in diagnosis and treatment can have
disastrous consequences so prompt recognition and treat-
ment are essential. The British Infection Society (the
predecessor of the British Infection Association) published
a consensus statement on the management of meningitis
and meningococcal sepsis in adults in 1999.1This was fol-
lowed by a management algorithm in 2003, which was pro-
duced and distributed by the Meningitis Research
Foundation.2 Since then, the epidemiology has changed,
especially following changes in immunisation programmes,
and there are new diagnostics and further data available
regarding adjunctive treatments. In addition, global in-
creases in the prevalence of antibiotic resistant bacteria
underlines the importance of good antimicrobial steward-
ship. The partner organisations for these updated guide-
lines formed a working party consisting of infectious
diseases physicians, neurologists, acute physicians,intensivists, microbiologists, paediatricians, public health
experts and patient group representatives to review the
literature published since 1999 and update the recommen-
dations in light of any new evidence. The working party
included representatives of the original authors from the
1999 consensus statement. The working party aimed to
create user-friendly, comprehensive guidelines primarily
for hospital-based clinicians in the UK with auditable out-
comes. In addition to the published manuscript there is
also an updated algorithm to aid emergency management.
Key changes are highlighted in Box 1. These guidelines
may also be useful to clinicians from other countries or set-
tings, although there are other international guidelines
available (Box 2).
Definitions
Some definitions are given in Table 1.
Epidemiology
Estimates of the incidence of bacterial meningitis and
meningococcal sepsis in the UK are derived from several
Box 1. Key Changes since consensus document in 1999.
 Updated epidemiology
 Change in recommendations regarding pre-hospital antibiotics
 Clear guidance on when to perform a CT scan
 Recommended durations of antibiotics and adjunctive treatment including the removal of activated protein C.
 Updated recommendations on empirical antibiotics
 Recommendations regarding outpatient treatment
 Updated guidance on prophylaxis for contacts
 Infection control advice
 The addition of a section on viral meningitis
 Audit tool
Box 2. Guidelines which may be of use in other settings.
 Infectious Diseases Society of America http://www.idsociety.org/uploadedFiles/IDSA/Guidelines-Patient_Care/
PDF_Library/Bacterial%20Meningitis%281%29.pdf
 European Federation of Neurological Sciences http://www.eaneurology.org/Guideline-Archive-by-topic.1358.0.
html
 European Society of Clinical Microbiology and Infectious Diseases Diagnosis and treatment of acute bacterial men-
ingitis (in press Feb 2016)www.escmid.org/escmid_library/medical_guidelines/escmid_guidelines/
 Federation of Infectious Diseases Society of Southern Africa http://www.sajei.co.za/index.php/SAJEI/article/
viewFile/528/686
 Ministry of Health, Social Services and Quality, Spain. http://www.guiasalud.es/GPC/GPC_525_EMI_ICS_compl_en.
pdf
Table 1 Definitions.
Meningism Symptoms of headache, neck stiffness and photophobia often associated with meningitis
Meningitis Inflammation of the meninges
Strictly a pathological diagnosis
Elevated cerebrospinal fluid white cell count and protein are normally used as indicators of
inflammation
Meningeal enhancement may be seen on contrast enhanced CT or MRI
Sepsis Presence of infection with systemic manifestations such as:  Fever or hypothermia
 Tachycardia
 Tachypnoea
 Altered mental state
(see the surviving sepsis guidelines for a full list of potential manifestations of sepsis41)
Severe sepsis Acute organ dysfunction secondary to documented or suspected sepsis
Septic shock Severe sepsis plus hypotension not reversed with fluid resuscitation
Meningococcal sepsis Evidence of sepsis with or without a characteristic petechial/purpuric skin rash and
hypoperfusion. Neisseria meningitidis may be identified from blood, CSF or skin lesions
(culture or PCR).
Invasive meningococcal
disease (IMD)
Invasion of any normally sterile site by Neisseria meningitidis including meningitis and
bacteraemia
Encephalitis Inflammation of the brain parenchyma
Strictly a pathological diagnosis
Elevated cerebrospinal fluid white cell count and protein normally used to indicate
inflammation
Parenchymal inflammation may be seen on MRI
Meningoencephalitis Inflammation of the meninges and adjoining brain parenchyma
Aseptic Meningitis Symptoms of meningism and raised numbers of cells in the CSF with a sterile bacterial culture.
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statutory notifications, Hospital Episode Statistics and the
Office of National Statistics. Although meningitis is a
notifiable disease in the UK and in other countries, it is
widely believed to be underreported.3,4 Several studies
have shown reductions in the frequency of bacterial menin-
gitis and meningococcal sepsis in recent years, although
these largely reflect changes seen in children. Disease in
adults has remained stable or increased.5,6 A recent study
in England and Wales showed an increase in the incidence
of meningitis in adults between 2004 and 2011, with an in-
crease of 3% per year in patients over 65 years of age. The
incidence in adults was estimated to be 1.05 cases per
100,000 population (between 2004 and 2011) with the high-
est incidence in the 45e64 age group (1.21 per 100,000).7
The mortality rate of community acquired bacterial menin-
gitis is high, approximately 20% for all causes and up to 30%
in pneumococcal meningitis, increasing with age.8,9
The number of cases of invasive meningococcal disease
(including meningitis and meningococcal sepsis) has
declined over the last decade in the UK, following the
introduction of the group C vaccine and the natural
variation of meningococci. Meningococcal disease has a
bimodal distribution with one peak in children less than 5
years of age and a second peak in the adolescent/early
adult age group.10e12 Amongst adults, the incidence of
meningococcal disease is highest in younger adults,Table 2 Key aetiological considerations for specific demograph
Young adults Viral meningitis m
e40s.
Second peak of m
Older adults Pneumococcal di
but remains rare
Skull fracture/CSF leak Pneumococcal m
Previous lymphocytic meningitis HSV-2 is the com
Rash Meningococcal m
pneumococcal m
Co-existing upper respiratory
tract infection e.g. otitis media,
sinusitis
Pneumococcal m
infection
HIV Positive Cryptococcal me
but should be co
TB meningitis an
Pneumococcal m
Other immunocompromised Asplenic individu
Streptococcus pn
influenzae.
Complement defi
Risk factors for l
alcohol depende
immunocomprom
Travel history An appropriate t
Toscana Virus (M
Eastern Europe),
Virus (USA), Lym
parasitic mening
following visits t
America or partsbetween the ages of 16e25.7,13 Other bacteria that cause
meningitis in adults include Listeria monocytogenes (most
commonly in older adults and the immunocompromised),
Streptococcus pyogenes, Enterococcus species, Group B
streptococcus, non-type B Haemophilus influenzae and
other gram negative bacteria such as Klebsiella, Pseudo-
monas and Enterobacter.7 Mycobacterium tuberculosis
should also be considered in those with appropriate risk
factors, even in patients with an acute presentation.
The likelihood of any specific aetiology depends on a
range of factors, see Table 2 for some key considerations
and risk factors. In many cases (34%e74%), no pathogen is
identified.14e19
Aims and scope of the guidelines
These guidelines cover the management of adults with
suspected and confirmed acute meningitis and meningo-
coccal sepsis, from pre-hospital care to post-discharge
support, including clinical features, investigations, treat-
ment, follow-up and prevention. As previously the guide-
lines focus on bacterial meningitis and meningococcal
sepsis but now also include a section on viral meningitis
which is increasing in relative importance. Meningitis in
immunocompromised individuals, post-surgical/iatrogenic
meningitis and tuberculous meningitis are beyond the scope
of these guidelines and not considered further. Guidelinesic groups.
ore common than bacterial, especially in women in their 20s
eningococcal disease in late teens/early 20s
sease more common in over 50s Listeria commoner in over 60s
.
eningitis and a risk factor for recurrent meningitis
monest cause of recurrent lymphocytic meningitis
eningitis more likely to present with a rash than
eningitis
eningitis is often associated with an upper respiratory tract
ningitis e commonest in those with a CD4 count <100  106
nsidered in anyone with a CD4 count of <200  106 or <14%.
important consideration at all CD4 counts
eningitis also increased
als are at increased risk from all encapsulated bacteria e.g.
eumoniae, Neisseria meningitidis and Haemophilus
ciency increases risk of meningococcal disease.
isteria meningitis include relative immunocompromise from
ncy, diabetes and malignancy as well as overt
ised from illness or medication.
ravel history may determine other rarer causes including
editerranean), Tick Borne Encephalitis Virus (Central and
other meningococcal (meningitis belt in Africa), West Nile
e disease (appropriate exposure in Europe or USA) and
itis (such as Naegleri fowleri e abundant globally occurring
o warm, fresh or brackish water, or trypanosomiasis e South
of Africa).
Box 3. Key questions.
 What are the indications for hospital admission?
 What should the pre-hospital management be?
 What are the clinical signs to look for including early recognition?
 What is the initial assessment and immediate action?
 Are prognostic or diagnostic scores of any value?
 What are the contraindication to LP?
 What are the indications for imaging?
 What investigations should be requested?
B Microbiological
B Biochemical
B Haematological
B Others (including travel related)
 When should an HIV test be offered?
 What treatment should be given?
B Empirical
B Directed
B Adjunctive
 What is the role of steroids?
 What is the role of glycerol?
 When should you refer to specialists/intensive care?
 What is the role for fluid management, inotropes and indications for ventilation?
 What should the intensive care management be?
 What preventative measures should/can be taken? (including notification and primary and secondary prevention)
 What are the appropriate infection control measures?
 Who should be screened for predisposing factors?
 What should follow up look like? (including the role of support services)
 How should viral meningitis be investigated and treated?
 What are the auditable measures? (to include an audit tool)
 When should this guideline be reviewed?
UK adult meningitis guidelines 409on the management of tuberculous meningitis20 and the
management of bacterial meningitis and sepsis in children
are available elsewhere.21
Methods
A literature search was performed in Medline for all English
language articles from the years 1999e2014 to identify all
publications since the first British Infection Society guide-
lines were published using the key words ‘meningitis’ AND
‘symptoms’; ‘signs’; ‘management’; ‘diagnosis’; ‘investiga-
tion’; ‘lumbar puncture’; ‘cerebrospinal fluid’; ‘computed
tomography (CT)’; ‘magnetic resonance imaging (MRI)’;
‘treatment’; ‘antiviral’; ‘antibiotic’; ‘steroids/dexametha-
sone’; ‘prevention’; ‘risk factors’ and ’immunocompromise’
separately and in combination with the following MESH
terms: (Viral, meningococcal, pneumococcal, Haemophilus,
bacterial). This yielded a total of 5027 citations. Theworking
party identified the main questions that we wanted to
address (see Box 3); titles and abstracts were reviewed by
one author (FM) to eliminate articles that were not relevant
to these questions. This left 621 articles which were then re-
viewed in full by 3 members of the writing group (BDM, FM,
SD) to remove any further articles that were felt not to be
helpful in answering the questions identified; mostly these
were case reports or studies relevant to specific populations
only. This resulted in 284 potentially relevant articles that
were made available to the whole working party. All authorscould also add to this core list of publications other articles,
for example those published before 1999; this includedmany
referenced in the original consensus statement.1 A further
literature search was done (by BDM and FM) prior to publica-
tion to identify any further relevant articles that had been
published in the interim.
Using this final list of articles each sectionwaswritten by a
primary author and reviewed by others from the working
party before being reviewed by the whole working party.
When a final draft was agreed upon by the working party it
was then sent for a first consultation to the boards and
councils of all the partner organisations and then a second
consultation to all themembers of the partner organisations.
A single document was assimilated in accordance with
the principles of the AGREE 2 (appraisal of guideline
research and evaluation) tool,22 and we used the GRADE
approach to grade the strength of evidence (see
Table 3).23 Where recommendations are not based on pub-
lished evidence but were agreed on by the working party,
they are graded as “authors’ recommendation” or “AR”.Presentation
Pre-hospital management
What are the indications for hospital admission and
what are the clinical signs to look for?
Table 3 GRADE rating system for the strength of the guidelines recommendations and the quality of the evidence.23
Strength of the recommendation Quality of the evidence
1 Strongly recommended A High quality e RCT, meta-analysis
2 Weakly recommended B Moderate quality e downgraded RCT or an upgraded
observational study
C Low quality e Observational study
D Very low quality e downgraded observational study.
a: Factors that may influence the grading of quality of evidence
Factors that might decrease the quality of evidence Factors that might increase the quality of evidence
Study Limitations Large magnitude of effect
Inconsistency of results Plausible confounding, which would reduce a demonstrated
effect
Indirectness of evidence Dose-response gradient
Imprecision
Publication bias
b. Factors that determine the strength of a recommendation
Balance between desirable and undesirable effects
Quality of evidence
Values and preferences
Costs of the intervention
RCT Z Randomised controlled trial.
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1. All patients where meningitis and/or meningococcal
sepsis is suspected in the community should be referred
to hospital for further evaluation and consideration of a
lumbar puncture (1C)
2. Rapid admission to hospital, via an emergency ambu-
lance, should be arranged so that, where possible,
the patient arrives within an hour of being assessed in
the community (AR)
3. Presence or absence of headache, altered mental sta-
tus, neck stiffness, fever, rash (of any description), sei-
zures and any signs of shock (e.g. hypotension, poor
capillary refill time) should be documented (1C)
4. Kernig’s sign and Brudzinski’s sign should not be relied
upon for diagnosis (2B)Rationale
The diagnosis of meningitis and meningococcal sepsis may
seem relatively straightforward in patients with classical
features of fever, headache, neck stiffness and altered
mental status in the case of meningitis or fever, purpuric
rash and shock in meningococcal sepsis but in many patients
someof these signswill beabsent.9,24,25 Theproblem for gen-
eral practitioners and acute physicians is to identify, from
the large number of patients who present with symptoms
consistent with meningitis or meningococcal sepsis, the
small minority of patients who do in fact have these condi-
tions and require urgent investigation and management.
Clinical features of meningitis
Urgent hospital referral is mandatory in adults in whom
meningitis or meningococcal sepsis is suspected in view ofthe possibility of rapid deterioration. The individual com-
mon clinical signs such as fever, vomiting, headache and
neck stiffness occur frequently in primary care and taken
independently are poor discriminators for meningitis.26
Combinations of symptoms and signs may be more useful
at identifying serious disease. Although bacterial meningitis
is of greater concern, clinical features alone cannot distin-
guish between viral and bacterial disease and in specific
populations, such as the elderly or immunocompromised,
the clinical presentation may be different. For example,
the elderly are more likely to have an altered conscious
level than their younger counterparts and less likely to
have neck stiffness or fever.27e29 Age can also be an indica-
tor of the likely causative agent. Listeria or pneumococcal
disease is more common in older people, viral meningitis
commonly occurs in adults in their 20se40s and meningo-
coccal infection in adolescents and young adults.5,14,27
In the largest single published study on bacterial men-
ingitis in adults Van de Beek and colleagues describe the
clinical and laboratory features in 696 episodes of bacterial
meningitis.9 The ‘classic triad’ of neck stiffness, fever and
altered consciousness was present in less than 50% of
cases.9 Other studies have shown similar findings.24,30,31 Pa-
tients with pneumococcal disease are more likely to have
seizures, focal neurological symptoms and a reduced
conscious level (as determined by the Glasgow Coma Scale
(GCS)). When a rash was present in the context of meningi-
tis, the causative organism was Neisseria meningitidis in
92% of cases (the rash was petechial in 89% of these). How-
ever, 37% of cases of meningococcal meningitis patients did
not have a rash. Kernig’s and Brudzinski’s signs are not
helpful in the clinical diagnosis of suspected meningitis;
they have been reported to have high specificity (up to
95%) but the sensitivity can be as low as 5%.24,32e35 As the
clinical features are often not clear cut, concern from
UK adult meningitis guidelines 411either the referring doctor or a relative should always be
taken seriously.36
In addition to the above, a history of travel, the
presence of a source of infection such as otitis media or
sinusitis, or contact with another person with meningitis or
sepsis should be ascertained.
Additional features of meningococcal sepsis and shock
Meningitis is the commonest presentation of meningococcal
disease, occurring in about 60% of patients. 10e20% of
patients may have evidence of shock or fulminant sepsis
with or without meningitis and up to 30% of patients may
have mild disease with just fever and a rash with no
evidence of either meningitis or shock.37 Meningococcal
sepsis can present with hypotension, altered mental state
and rash; typically this is purpuric or petechial in nature
but it may take other forms including a maculopapular
rash. Patients with meningococcal sepsis can deteriorate
rapidly, and shock ensues; they must be monitored
frequently even if they initially look well.
Shock in meningococcal sepsis results from a combina-
tion of hypovolaemia (caused by capillary leak syndrome),
myocardial dysfunction, altered vasomotor tone and in
some instances, adrenal insufficiency.38,39 The clinical fea-
tures of shock arise because perfusion of the vital organs
(such as the brain and heart) is maintained at the expense
of perfusion of the skin, kidneys and gut. In the early phases
of shock these processes compensate for hypovolaemia and
maintain central circulating blood volume, blood pressure
and cardiac output. As a result, patients with meningo-
coccal sepsis often present with cold peripheries and pro-
longed capillary refill time as well as oliguria. In the most
severe cases, ischaemia of the skin or even whole limbs
may occur, particularly if there is thrombosis in areas of
vascular stasis. In addition, many patients with septic shock
will develop renal dysfunction, often leading to acute kid-
ney injury.11 The pathophysiology is fully reviewed by
Pathan and colleagues.40
Despite severe shock, in healthy young people and
adolescents preservation of brain perfusion and function
is often maintained until relatively late, so that the young
person’s relatively alert state may make nursing and med-
ical staff under-estimate the degree of cardiovascular
collapse. Eventually cerebral dysfunction indicates loss of
cerebral vascular homeostasis and reduced brain perfusion.Box 4. Risk factors for a fatal outcome in
meningococcal disease.
Rapidly progressing rash
Coma
Hypotension and shock
Lactate >4 mmol/L
Low/normal peripheral white blood cell count
Low acute phase reactants
Low platelets
Coagulopathy
Absence of meningitisThe onset of hypotension signifies a failure of the
compensatory mechanisms. It should be remembered that
shock in young people is not always accompanied by the
presence of arterial hypotension (cryptic shock), but may
be indicated by the presence of a high blood lactate level
(>4 mmol/L). Risk factors for a fatal outcome in meningo-
coccal sepsis are shown in Box 4.
The Surviving Sepsis guidelines also provide additional
guidance on the management of patients with suspected
sepsis.41
Should antibiotics be given prior to admission?
Recommendations
5. Antibiotics should be given to patients in the commu-
nity in whom there are signs of meningococcal disease
e.g. a rash in combination with signs of meningism or
severe sepsis (1D)
6. Antibiotics should be given to patients in the commu-
nity in whom there are signs of severe sepsis e.g. hypo-
tension, poor capillary refill time, altered mental state
(1D)
7. Antibiotics should be given to patients in the commu-
nity, with suspected meningitis, who will have a delay
of more than one hour in getting to hospital (2D)
8. If antibiotics are given in the community they should be
in the form of Benzylpenicillin 1200 mg IM or IV, or a
third generation cephalosporin such as Cefotaxime
(2 g) or Ceftriaxone (2 g) IM or IV (1C)
9. In the case of known anaphylaxis to penicillins or ceph-
alosporins, antibiotics should not be given until admis-
sion to hospital (AR)
10. The administration of parenteral antibiotics should not
delay transfer to hospital (1D)Rationale
The aim of pre-hospital antibiotics is to reduce the mor-
tality associated with delays in antibiotic therapy.42e45
However there are some drawbacks to this approach; these
include the risk of allergic reaction to the antibiotic and the
need to consider concurrent steroid administration to
reduce complications associated with pneumococcal men-
ingitis. In addition, antibiotic treatment before lumbar
puncture (LP) can alter the initial diagnostic investigations,
reducing the likelihood of identifying bacteria from cere-
brospinal fluid (CSF) culture, and may lead to the misdiag-
nosis of bacterial meningitis as viral.46,47 Molecular
diagnostics such as the polymerase chain reaction (PCR),
can detect pathogens up to 9 days after antibiotics have
been given48,49 but they do not give antibiotic susceptibil-
ities which remain vital.
Two systematic reviews investigating pre-hospital anti-
biotics in meningococcal meningitis have been carried out
in recent years.50,51 One50 only identified a single trial,
based during an epidemic in Niger, that met their inclusion
criteria of randomised (or quasi randomised) controlled tri-
als comparing antibiotics with placebo/no intervention.52
The other identified 14 studies, all of which were observa-
tional. The studies used oral or parenteral antibiotics and
five stratified by disease severity. Overall these systematic
Box 5. Indications for neuroimaging before
lumbar puncture (LP) in suspected
meningitis*.
 Focal neurological signs
 Presence of papilloedema**
 Continuous or uncontrolled seizures
 GCS £ 12***
*to exclude significant brain swelling and shift that
may predispose to cerebral herniation post LP.
**inability to view the fundus is not a contraindication
to LP, especially in patients who have had a short dura-
tion of symptoms.
*** LP without prior neuroimaging may be safe at levels
below this.
412 F. McGill et al.reviews do not provide evidence for or against the use of
pre-hospital antibiotics and it is unlikely further rando-
mised controlled trials will be undertaken. However, given
the evidence that in general early antibiotics reduce mor-
tality, it would seem prudent that they are used as soon
as possible in patients with a strong suspicion of bacterial
meningitis, especially if there are signs indicative of a
worse outcome,53 or where there may be a delay in hospital
admission. Pre-hospital antibiotics should also be given if
the patient is thought to have meningococcal disease in
view of the potential for rapid catastrophic deterioration.
If antibiotics are given in the community this must not delay
hospital admission. As benzylpenicillin, cefotaxime and cef-
triaxone have good CSF penetration in inflamed meninges
and can be given via the intramuscular route as well as
intravenously they are good options for use in the commu-
nity. If there is known anaphylaxis to these beta-lactam an-
tibiotics, treatment should be delayed until admission to
hospital when appropriate antibiotics can be given.
Immediate action within the first hour of arriving at
hospital
What should the initial hospital assessment and imme-
diate action be?
Recommendations
11. Stabilisation of the patient’s airway, breathing and cir-
culation should be an immediate priority (AR).
12. A decision regarding the need for senior review and/or
intensive care admission should be made within the first
hour (AR).
13. The patient’s conscious level should be documented us-
ing the Glasgow coma scale (2C).
14. Blood cultures should be taken as soon as possible and
within 1 h of arrival at hospital (AR)
15. In patients with suspected meningitis (with no signs of
shock or severe sepsis)
B LP should be performed within 1 h of arrival at hos-
pital provided that it is safe to do so (1D)
B treatment should be commenced immediately af-
ter the LP has been performed, and within the first
hour (1B)
B If the LP cannot be performed within 1 h treatment
should be commenced immediately after blood
cultures have been taken and LP performed as
soon as possible after that (1B)
16. In patients with predominantly sepsis or a rapidly
evolving rash:
B Antibiotics should be given immediately after
blood cultures have been taken (AR)
B Fluid resuscitation should be commenced immedi-
ately with an initial bolus of 500 ml of crystalloid
(1B)
B The Surviving sepsis guidelines should be followed
(AR)
B LP should not be performed at this time (1D)
17. All clinicians managing such patients should have post-
graduate training on the initial management of acute
bacterial meningitis and meningococcal sepsis [AR]18. Patients with meningitis and meningococcal sepsis
should be cared for with the input of an infection
specialist such as a microbiologist or a physician with
training in infectious diseases and/or microbiology [AR].
Rationale
The priority for patients admitted with suspected meningi-
tis is to a) stabilise their airway, breathing and circulation,
b) begin appropriate investigations, and c) instigate prompt
treatment. These three things should largely happen
concurrently. All patients should be reviewed by a senior
clinician. The Royal College of Physicians recommend
consultant review for all acute medical patients within
14 h of admission. Most patients with suspected meningitis
or meningococcal sepsis should be seen much earlier than
this. The need for urgent review should be assessed early
using the National Early Warning Score.54 An aggregate
score of 5/6 (or a score of 3 in any single physiological
parameter) should prompt an urgent review by a clinician
competent to assess acutely ill patients; a score of 7 or
more should prompt an urgent assessment by a team with
critical care competencies. Clinicians should, however,
not be falsely reassured if the early warning score is lower
than these parameters, because patients with meningitis,
and meningococcal sepsis in particular, can deteriorate
rapidly. In addition the presence or absence of a rash and
the use of pre-admission antibiotics should be recorded
for all patients. The GCS should be recorded both for its
prognostic value, and to allow changes to be monitored.
A GCS of 8 is associated with a poor outcome.55 The
GCS also helps with decisions about whether it is safe to
perform a LP (see Box 5). Blood cultures should be taken
as soon as possible and certainly within 1 h of presentation,
prior to the prompt administration of antibiotics.41
Patients with suspected meningitis (without shock or any
signs of meningococcal sepsis)
Ideally the LP should also be performed before starting
antibiotics in order to allow the best chance of a definitive
diagnosis. This may require the equipment, facilities and
personnel to carry out LPs to be available within the
Box 6. Initial therapeutic endpoints in the
resuscitation of septic shock41
Capillary refill time less than 2 s
Normal blood pressure for age
(in adults > 65 mmHg mean BP)
Normal pulses with no differential between
peripheral and central pulses
Warm extremities
Urine output >0.5 ml/kg/hour (A urinary
catheter is required)
Normal mental status
Central venous pressure 8e12 mmHg
Lactate < 2 mmol/L
UK adult meningitis guidelines 413emergency department. The need for a rapid LP has to be
weighed against the desire to start antimicrobial treatment
urgently.56 Even if treatment has been initiated, a LP
should still be performed as soon as possible, preferably
within 4 h of commencing antibiotics, to help identify the
cause of meningitis. The culture rate can drop off rapidly
after that time and it can become difficult to identify the
causative bacteria in cases of bacterial meningitis.56 Intra-
venous antibiotics should be given promptly in hospital as
there is evidence that delays increase mortality.43e45
Patients with suspected meningococcal sepsis, suspected
meningitis with shock or a rapidly evolving rash
In patients with suspected meningococcal sepsis, or men-
ingitis with shock, the priority is circulatory stabilization
although there is conflicting evidence surrounding the
amount and type of fluid to be used. In shocked patients
fluid resuscitation should be given carefully in boluses of
500 ml monitoring the patient for fluid overload with an
initial fluid bolus of 500 ml of crystalloid given rapidly (over
5e10 min). Shock may be rapidly reversed by this initial
fluid bolus, but repeated review is necessary. In such
critically ill patients careful fluid resuscitation should
continue, aiming to achieve the therapeutic endpoints for
surviving sepsis shown in Box 6.41 Vasopressors may be
necessary if shock does not respond to initial fluid chal-
lenges but this should be instituted in a critical care
setting. In keeping with international guidance on the man-
agement of sepsis, if there are any signs of severe sepsis or
septic shock antibiotics should be given immediately and
certainly within the first hour.41
Bacterial meningitis and meningococcal sepsis are rare
medical emergencies. Therefore, it is essential that all
doctors who may encounter a case are adequately trained.
In addition specialists in the management of infectious
diseases should be consulted early as there is some
observational evidence that patient outcomes are improved
if they are managed by a specialist.56
Lumbar punctures and imaging
Which patients with suspected meningitis should have
a lumbar puncture (LP)?Recommendations
1. Patients should not have neuroimaging before their LP
unless there is a clinical indication suggestive of brain
shift (see Box 5) (1D)
2. If prior neuroimaging is indicated an LP should be per-
formed as soon as possible after the neuroimaging
unless:
a. neuroimaging reveals significant brain shift (1D)
b. An alternative diagnosis is established (AR)
c. The patient’s clinical condition precludes an LP by
having continued seizures, rapidly deteriorating
GCS or cardiac/respiratory compromise (AR)
3. Regardless of neuroimaging considerations LP should be
delayed/avoided in the following situations (AR):
a Respiratory or cardiac compromise
b. Signs of severe sepsis or a rapidly evolving rash
c. Infection at the site of the LP
d. A coagulopathy
When should a lumbar puncture be performed in pa-
tients who are on anticoagulants?
Recommendations
4. If a neurological infection is suspected on admission
prophylactic subcutaneous low molecular weight hepa-
rin (LMWH) should not be started until 4 h after the LP
is performed (AR)
5. In patients already on prophylactic LMWH the LP should
not be performed until 12 h after the dose (AR)
6. Prophylactic LMWH should be delayed until 4 h after a
LP (AR)
7. Patients on therapeutic LMWH should not have an LP
until 24 h after a dose (AR)
8. Therapeutic intravenous unfractionated heparin can be
restarted 1 h after an LP (2C)
9. In patients on warfarin LP should not be performed un-
til INR is 1.4 (2D)
10. Patients on aspirin and other non-steroidal anti-inflam-
matories do not need to have their LP delayed (1C)
11. In patients on clopidogrel an LP should be delayed for 7
days or until a platelet transfusion or desmopressin
(DDAVP) is given e these should be discussed with a
haematologist and the risk benefit ratio of performing
a LP discussed (AR)
12. Expert advice, from a haematologist, must be sought
for those patients on newer anticoagulants such as
apixaban, dabigatran etexilate and rivaroxaban (AR)
13. In patients with known thrombocytopenia LP should not
be performed at platelet counts of <40  109/L or with
a rapidly falling platelet count (1D)
14. LP should not be delayed for the results of blood tests
unless there is a high clinical suspicion of a bleeding
diathesis (AR)
15. In situations where a LP is not possible immediately, this
should be reviewed at 12 h and regularly thereafter (AR)
Should diagnostic scoring systems be used?
16. Diagnostic scoring systems are not recommended (1D).
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A LP is an essential investigation in the management of
patients with suspected meningitis. In the majority of
patients this can be performed without prior neuroimaging,
though this has been a controversial area.57e60 Performing a
CT scan before the LP is associated with delays in antibi-
otics, which in turn can lead to an increase in mortality.15,43
A CT scan should only be performed if there are clinical
signs suggestive of a shift of brain compartments. This is
because there is a theoretical risk that a lumbar puncture,
by lowering the pressure, might make such shift worse, re-
sulting in a brain herniation syndrome. If there are signs
suggestive of brain shift, the CT scan may identify any
space occupying lesions, brain swelling or shift, although
these may occur in the context of a normal brain CT.59
The CT scan does not detect raised intracranial pressure.
The clinical features indicative of a possible shift of brain
compartments include focal neurological signs and a
reduced GCS (Box 5). The exact level of GCS at which a
CT scan is indicated is debated.9,21,57e59,61,62 A range of
values has been suggested ranging from a GCS of <8 to
<13.63,64 Some guidelines just state ‘abnormal level of con-
sciousness’,65 meaning obtunded/not alert or unrespon-
sive.59 We recommend that an LP can be performed
without prior neuroimaging if the GCS is >12 and may be
safer at lower levels. Those with a GCS 12 will require a
brain scan but should first be assessed by a critical care
physician and intubation may be considered.
Of note, in 2009, the Swedish guidelines for the man-
agement of meningitis changed their recommendations and
removed altered conscious level as an indication for CT
before LP. A subsequent study compared the management
of approximately 400 patients before and 300 after the
change in guidelines; it showed that after the change,
antimicrobial treatment was started on average 1.2 h
earlier, and the mortality was lower, (6.9% vs 11.7%) with
a lower risk of sequelae (38% vs 49%).66 Whilst there may
have been other changes implemented during this time
period that led to the improved outcomes it does support
the fact that patients do not suffer excess harm or mortal-
ity when an LP is performed without a CT scan.
Some authorities also suggest ‘immunocompromise’ as
a reason to perform a CT scan before an LP. Whilst we
recognise that immunocompromised patients may be more
at risk of intracranial mass lesions we find no evidence
that they would be at any increased risk of cerebral
herniation if they presented without the clinical signs
indicated in Box 5.
If neurological imaging is performed and no contraindi-
cation is found the LP should be performed as soon as
possible afterwards (unless an alternative diagnosis has
been made in the interim).
Lumbar puncture and clotting abnormalities
Subdural haematoma is a potential complication of an LP;
although the exact incidence of post-LP haematomas is
unknown the risk is increased if the LP is performed in patients
with abnormal clotting. However, there is little objective
evidence on which to guide safe clotting parameters for LP in
patients with neurological infections. In line with the UK
Department of Health’s recommendations on venothrom-
boembolic disease67 we recommend for patients already onprophylactic LMWH the LP should not be performed until
12 h after the last dose. If patients have not commenced on
LMWH the LP should be performed as soon as possible and pro-
phylactic LMWHcan be started 4 h afterwards. The duration of
action of LMWH will be longer in patients with severe renal
impairment and coagulation parameters such as the APTTr,
may need to be checked in such cases.67,68 For patients who
are on higher doses of LMWH an LP should not be performed
within 24 h of therapeutic LMWH.69
There have been large observational studies evaluating
unfractionated heparin and spinal or epidural anaesthesia. In
these studies the risk of spinal haematomas was negligible in
patients in whom the heparin was given after at least
60 min.70,71 Extrapolating from this we recommend that un-
fractionated heparin can be restarted 1 h after an LP.
In patients on warfarin the risks of reversing the warfarin
will need to be weighed against the benefits of performing an
LP. An LP should not be routinely performed at an INR of
1.5.72,73 Therapy with aspirin or non-steroidal anti-inflam-
matory medications alone does not increase the risk of spinal
haematoma after LP74 and LP does not need to be delayed in
patients who are taking these drugs. Clopidogrel inhibits
platelet aggregation for the whole lifespan of the platelet
which is between 7 and 10 days.75 If the benefits of performing
the LParedeemed tooutweigh the risks, in consultationwith a
haematologist, a platelet transfusion can be given 6e8 h after
the last dose of clopidogrel) prior to LP. Patients receiving the
newer oral anticoagulants such as apixaban, dabigatran etex-
ilate and rivaroxaban should be discussed with a haematolo-
gist. Trials are ongoing regarding specific reversal agents for
these drugs and a monoclonal antibody fragment, specifically
aimed at dabigatran, has recently been approved by the Euro-
pean Medicines Agency.76 There may be a role for reversal
agents prior to LP in the future but these cases should be dis-
cussed with a specialist.
The evidence regarding a platelet count at which it is safe
to perform a LP mostly comes from patients with haemato-
logical malignancies, obstetric patients and patients
requiring regional anaesthesia. The risk of the procedure
must be balanced against the benefits of having a definitive
diagnosis. A recent review of the literature by van Veen has
suggested thataplatelet countof>40 109/L is safeand that
even lower countsmay be acceptable, depending on the indi-
vidual case.77 In addition to the absolute platelet count both
the trend and the cause of thrombocytopenia must be taken
into consideration: a rapidly falling platelet count is likely to
be a higher risk than a stable thrombocytopenia; similarly,
thrombocytopenia secondary to chronic idiopathic thrombo-
cytopenic purpura probably carries a lower risk than throm-
bocytopenia due to DIC. The majority of the studies (five of
seven) identified in van Veen’s review were in paediatrics,
and all were in patients with cancer and not infection. In
the patients who developed complications after LP this was
almost always in the presence of another risk factor such as
rapidly falling platelet count, other coagulopathy or trau-
matic LP. Unless there is a strong suspicion that the patient
will have a clotting abnormality the LP should not be delayed
to await the results of blood tests.
If there is any reason to delay the LP initially this
decision should be reviewed regularly and consideration
given to performing the procedure later if the diagnosis has
not been confirmed by other means.
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complication following LP and can occur in up to a third of
patients.78 Some methods and myths associated with the
prevention of a post LP headache are shown in Box 7.
Diagnostic scoring systems
Several scoring systems have been developed to try and help
clinicians differentiatebacterialmeningitis fromother forms
ofmeningitis, especially viral, basedmostly on the initial CSF
findings.79e87 This is because CSF culture results can take
some time, and an early indicator, based on initial CSF re-
sults, would allow unnecessary antibiotics to be stopped
and patients deemed to have viral meningitis to be dis-
charged. In addition to requiring CSF data, many rely on
plasma glucose, which is often not performed; while others
require complex calculations which are impractical in a
busy acute medical setting. Most have been developed in
paediatric settings, only been tested retrospectively and
have not been externally validated although there has been
a recent score developed prospectively for adults87). No clin-
ical predictor tool has been widely translated to use in
routine clinical practice andwedo not recommend their use.
Investigations
Laboratory investigations help establish the aetiology of
meningitis and sepsis, especially differentiating between
viral and bacterial causes, identify antibiotic resistant
organisms, assist with prognosis and guide public health
management including infection control, immunisation for
the patient and contacts, and antibiotic prophylaxis
(Fig. 1).
What investigations should be performed for sus-
pected meningitis or meningococcal sepsis?
Recommendations
1. In all patients with suspected meningitis and/or menin-
gococcal sepsis blood should be sent for:
a. Culture (prior to antibiotics wherever possible) (1C).
b. If antibiotics have been given in the community
blood cultures should be taken as soon as possible
on arrival in hospital (within the first hour) (1C)
c. Pneumococcal and meningococcal PCR (EDTA sam-
ple) (1C)
d. Storage, to enable serological testing if a cause is
not identified (a convalescent serum sample should
also be sent 4e6 weeks later e discuss with microbi-
ologist) [1C]
e. Glucose measurement (1C)
f. Lactate measurement (1C)
g. Procalcitonin (if available) (2C)
h. Full blood count, urea, creatinine, electrolytes,
liver function tests and clotting screen
2. In all patients in whom a LP is performed the following
should be documented/requested: [1C]
a. CSF opening pressure (unless the LP is performed in
the sitting position).
b. CSF glucose with concurrent plasma glucose
c. CSF proteind. CSF lactate (if prior antibiotics have not been given)
(2B)
e. CSF for microscopy, culture and sensitivities
3. CSF PCR for pneumococci and meningococci should be
performed in all cases of suspected bacterial meningi-
tis[1C]
4. CSF should be stored for later tests if initial investiga-
tions do not yield a pathogen [1C]
5. A swab of the posterior nasopharyngeal wall should be
obtained as soon as possible, and sent for meningo-
coccal culture, in all cases of suspected meningococcal
meningitis/sepsis [1C]
6. Any significant bacterial isolates (including meningo-
cocci identified from the nasopharynx) should be sent
to the relevant national reference laboratory for sero-
typing [1C]
Rationale
Blood tests
Blood cultures should be taken in all cases of suspected
bacterial meningitis or meningococcal sepsis. Ideally this
should be before any antibiotics are given, when the yield
can be as high as 74%. If a patient received antibiotics
before hospital admission, blood cultures should be taken
as soon as possible after arrival in hospital. Non-culture
diagnostics approaches to pathogen identification, such as
PCR, are becoming increasingly important. PCR of periph-
eral blood increases the laboratory confirmation rate in
meningococcal disease substantially, especially as it will
remain positive for several days after antibiotics have been
initiated.88 There are fewer data on the sensitivity and
specificity of blood PCR in patients with pneumococcal
meningitis, though a small paediatric study showed it to
be useful,89 and a multiplex PCR was highly sensitive in
another study.90 There is a concern that in children PCR
of blood for pneumococci can be positive without evidence
of invasive disease, presumably because of asymptomatic
carriage,91 the same has not been shown in adults. Howev-
er, in adults with features of bacterial meningitis a positive
PCR in the blood can be a useful adjunct for diagnosing the
aetiological cause.
Serological assays may also play a role in the diagnosis of
meningitis caused by mumps, syphilis or Lyme disease for
example. If no pathogen is identified on first line testing, an
acute serum sample should be taken and stored and a
convalescent sample taken at 4e6 weeks. These tests
should be discussed with local infection specialists.
Glucose must be taken at the same time as the LP in
order to allow interpretation of the CSF glucose. Lactate
measurement is useful in the management of anyone with
suspected sepsis and if raised can provide useful guidance
for resuscitation (Box 6).
Serum procalcitonin can be helpful for the differentia-
tion of bacterial and viral infections. It has a sensitivity of
95% and a specificity of 100% (PPV e 97e100%; NPV e
93.9e100%) for distinguishing bacterial meningitis from
viral in adults.92,93 Its routine use is limited by its availabil-
ity and cost although a recent meta-analysis has suggested
it might be cost effective in the paediatric setting.94 A
recent technology assessment by the UK National Institute
Box 7. Methods to reduce headache post lumbar puncture.
Definition and aetiology
Headache following a lumbar puncture (LP) typically has a low-pressure phenotype; i.e. worse upright and better lying
flat. It is usually caused by a dural tear sustained at the time of LP and does not relate to the volume of cerebrospinal
fluid (CSF) taken. In most cases it is self-limiting although a few patients may require a blood patch for persistent
headache, and rarely the low pressure may be associated with the development of subdural haematomas.
Practices associated with reduced risk of post-LP headache
1. Finer gauge needles274,275
2. Risk of headache decreases with smaller gauge needles, but this needs to be balanced with the length of time the
procedure will take with a very fine needle. Practically a 22G needle is probably the smallest that can be used.
3. Non-traumatic (less traumatic) needles275,279
 Paraesthesia rate and failure rate may be higher with these needles
4. Orientation of the bevel of the needle in a transverse plane (perpendicular to the longitudinal axis)277,278
 This is probably less important if an atraumatic needle is being used.
5. Replacement of the stylet before withdrawing the needle280
6. Experience of performing LPs and number of attempts at LP281
 Fewer attempts at dural puncture is thought to be associated with a decreased incidence of headache after lumbar
puncture.
Practices NOT proven to reduce risk of post LP headache
1. Reducing the volume of CSF taken282
 There is no evidence that the amount of CSF removed influences the incidence of post LP headache
2. Bed rest283,284
 Patients are often advised to lie recumbent for a period of time after an LP but there is no evidence that this reduces
the risk of headache.
3. Hydration285
 There has only been one study looking at fluid post LP as a preventative strategy and it showed no difference between
those who took 1.5 L and those who had 3 L post LP.
4. Caffeine
 There have been some experiments looking at IV caffeine to treat post LP headache but there is no evidence that either
oral or IV caffeine can prevent the headache.
416 F. McGill et al.of Health and Care Excellence (NICE) has found that whilst
procalcitonin assays show promise there is currently insuffi-
cient evidence to recommend routine adoption into the
NHS. However, it should be noted that they did not consider
any studies looking at meningitis. They also accepted that
some centres do use procalcitonin to guide management
e these centres were encouraged to take part in relevant
data collection and research. As a result we continue to
recommend the use of procalcitonin if it is available.95CSF
Initial CSF analysis of cells protein and glucose helps
determine the likely cause of meningitis; subsequent mi-
croscopy and culture can confirm the aetiology and antibi-
otic susceptibilities. The use of pre-prepared LP packs, with
all the necessary sampling tubes may increase the diag-
nostic yield.96 Often inappropriately small volumes of CSF
are taken limiting the number of investigations that can
be performed. As CSF is produced at a rate of approxi-
mately 22 ml/h (similar to urine) amounts of at least
15 ml can be safely removed from adults.97,98
CSF opening pressure should always be measured when
doing a lumbar puncture (unless it is done in the sittingposition, when it will be artificially raised because of the
positioning). The opening pressure is normally elevated
above 20 cm CSF in bacterial meningitis, and is often
higher.9
CSF cell count
In acute bacterial meningitis there is classically a poly-
morphonuclear pleocytosis in the CSF (see Table 4) but
there are always exceptions to the rule. There can be min-
imal, even no white cells, especially early on in the course
of the illness; in one study 10% of patients had fewer than
100 cells per mm3.9,99,100 There may be a predominance
of lymphocytes in some cases of bacterial meningitis e.g.
listeria or partially treated bacterial meningitis.101 A pre-
dominance of neutrophils may also be seen in early viral
meningitis,102 especially enteroviral disease, although
such patients are unlikely to have a total CSF white cell
count of over 2000 cells per mm3.81
CSF biochemistry
The CSF glucose, protein and lactate are all useful for
differentiating viral, bacterial and other causes of menin-
gitis. The values can give valuable pointers to the likely
Pa?ent with Suspected Meningi?s (and 
no signs of shock or severe sepsis) 
Pa?ent with Suspected Meningococcal 
sepsis 
Bloods Blood Cultures 
Full blood count, urea, crea?nine, 
electrolytes, liver func?on tests and 
clo?ng screen 
Procalcitonin (or CRP if unavailable) 
Meningococcal and Pneumococcal PCR 
Serology sample 
Glucose 
CSF Opening Pressure 
Microscopy, Culture and Sensi?vity 
Meningococcal and Pneumococcal PCR 
Protein 
Glucose  
Lactate 
Throat swab Bacterial Culture Bacterial Culture  
Further tests    (if no ae?ology iden?fied on first panel) 
If bacterial meningiƟs seems likely:
16S rRNA PCR on CSF 
If viral meningiƟs seems likely: 
CSF PCR for:  
HSV 1, HSV 2, VZV and Enterovirus. 
Stool for Enterovirus PCR  
Throat swab for Enterovirus PCR 
If any of the following features are 
present LP should be delayed: 
Signs of severe sepsis or rapidly 
evolving rash 
Respiratory or cardiac compromise 
AnƟcoagulant therapy/known 
thrombocytopenia 
InfecƟon at the site of LP 
Focal neurological signs †
Presence of papilloedema*†
ConƟnuous or uncontrolled seizures†
GCS ≤12**†
* inability to see the fundus is not a 
contraindicaƟon to LP 
** LP may be safe at lower levels of 
consciousness 
†Neuroimaging should be performed before LP 
for these indicaƟons. 
Once the paƟent is stable and if 
meningiƟs is likely (with or without 
sepsis) an LP may sƟll be diagnosƟcally 
useful, even aŌer several days. 
Blood Cultures 
Full blood count, urea, crea?nine, 
electrolytes, liver func?on tests and 
clo?ng screen 
Procalcitonin (or CRP if unavailable) 
Meningococcal and Pneumococcal PCR 
Serology sample 
Glucose 
PCR-Polymerase Chain Reac?on; CSF – cerebrospinal fluid; HSV – herpes simplex virus; VZV – varicella zoster virus; LP 
– lumbar puncture; CRP – C-reac?ve protein; GCS – Glasgow Coma Scale; rRNA – ribosomal ribonucleic acid 
Figure 1 Investigations algorithm.
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between the different diseases. Bacterial meningitis tends
to have a higher CSF protein than viral meningitis and one
study found that a patient is unlikely to have bacterial
disease if the CSF protein is less than 0.6 g/L.103 The CSF
glucose is lowered in bacterial meningitis; however the
concentration also varies according to the plasma glucose
and so the CSF:plasma glucose ratio should be used. Nor-
mally CSF glucose is about two thirds of the plasma glucose.
In bacterial meningitis the ratio is usually significantly
lower than this, a CSF:plasma glucose ratio cut off of 0.36
for diagnosing bacterial meningitis has a high sensitivity
and specificity (93%).104 Unfortunately plasma glucose is
often not performed in clinical practice, and so the CSF
glucose must be interpreted in isolation. One report suggest
a CSF glucose of above 2.6 mmol/L is unlikely to be associ-
ated with bacterial meningitis.105 No CSF parameters givean absolute indication of cause, and any CSF results must
be interpreted in the context of the clinical presentation.
CSF lactate has a high sensitivity and specificity (93% and
96% respectively) in distinguishing between bacterial and
viral meningitis if antibiotics had not been given before-
hand. A CSF lactate cut off of 35 mg/dl has been suggested
to have the best sensitivity for distinguishing between
bacterial and viral meningitis. If patients have received
antibiotics the sensitivity drops to less than 50%.106 The
high negative predictive value makes it a useful test, if
done prior to commencing antibiotics, to rule out bacterial
meningitis and reassurance to stop or withhold antibiotics.
CSF gram stain and culture
Gram stain of the CSF is a rapid method for detecting
bacteria with a sensitivity of between 50 and 99% (depen-
dent on organism and prior antibiotics) and a specificity of
Table 4 Classical CSF Features of the different causes of meningitis.
Normal Bacterial Viral Tuberculous Fungal
Opening Pressure
(cm CSF)
12e20 Raised Normal/mildly
raised
Raised Raised
Appearance Clear Turbid, cloudy,
purulent
Clear Clear or cloudy Clear or cloudy
CSF WCC (cells/uL) <5 Raised
(typically >100)a
Raised
(typically 5e1000)a
Raised
(typically 5e500)a
Raised
(typically 5e500)a
Predominant cell type n/a Neutrophilsb Lymphocytesc Lymphocytesd Lymphocytes
CSF protein (g/L) <0.4 Raised Mildly raised Markedly raised Raised
CSF glucose (mmol) 2.6e4.5 Very low Normal/slightly low Very low Low
CSF/plasma glucose
ratio
>0.66 Very low Normal/slightly low Very low Low
CSF e cerebrospinal fluid; WCC e white cell count.
Local laboratory ranges for biochemical tests should be consulted and may vary from these quoted here.
A traumatic lumbar puncture will affect the results by falsely elevating the white cells due to excessive red cells. A common correction
factor used is 1:1000.
a Occasionally the CSF WCC may be normal (especially in immunodeficiency or tuberculous meningitis).
b May be lymphocytic if antibiotics given before lumbar puncture (partially treated bacterial meningitis), or with certain bacteria e.g.
Listeria monocytogenes.
c May be neutrophilic in enteroviral meningitis (especially early in disease).
d May be neutrophils early on in the course of disease.
418 F. McGill et al.97e100%.9 Cytospin centrifugation of CSF can increase the
yield.107 The gold standard for the diagnosis of bacterial
meningitis is CSF culture. Depending on whether prior anti-
biotics have not been given, and depending on the infecting
organism, it is diagnostic in 70e85% of cases of bacterial
meningitis.108 CSF sterilization may occur within the first
2 h of administration of antibiotics for meningococci and
within 4 h for pneumococci.109 However, even if rendered
culture negative, CSF analysis may be helpful up to 48 h af-
ter commencing parenteral antibiotics.
CSF PCR
CSF PCR can rapidly identify the causative organism in
meningitis and is especially useful if antibiotics have been
given prior to LP. PCR has a sensitivity of 87e100% and
specificity of 98e100%110e113. If an organism cannot be
identified by pathogen specific PCR, then PCR for 16S ribo-
somal RNA, which is present in almost all bacteria may be
used, although it has lower specificity.114 Multiplex PCR
and other platforms that can detect multiple pathogens
at the same time are increasingly being trialled and can
reduce time and increase sensitivity.115e117 We would
recommend that each diagnostic laboratory evaluate any
tests prior to use.
Latex agglutination tests
The bacteria commonly causing meningitis carry specific
polysaccharide surface antigens that can be detected by
agglutination tests on the CSF. They have largely been
surpassed by the use PCR and are not recommended except
in large outbreak situations where rapid PCR is not
available.
Some CSF should also be stored in order to be used for
further investigations if necessary.
Nasopharyngeal isolates
Meningococci can be isolated from the nasopharynx in up to
50% of patients with meningococcal disease. If patientshave started antibiotics nasal swabs may still be positive
when blood and CSF cultures are negative, although these
data predates the widespread use of empirical cephalospo-
rins.118 Given that many patients are diagnosed by PCR
alone (in the blood and/or CSF), without a cultured isolate,
nasopharyngeal swabs should be taken to attempt to grow
an organism which is important for surveillance and deter-
mination of vaccine coverage. Such isolates are almost al-
ways identical to those from their blood or CSF (when
culture of these samples has been successful)119,120 but
the possibility of asymptomatic and irrelevant carriage
should be considered e especially if the clinical picture is
not compatible with acute meningococcal meningitis. All
significant isolates (from any site) should be referred to
the relevant reference laboratory.
Streptococcus pneumoniae is also carried asymptomati-
cally in the nose but there are often multiple strains and
it is not clear that the strain in the nose is definitely related
to that which causes meningitis, hence nasal swabbing is
not recommended for pneumococcal disease.
Treatment
What antibiotic treatment should be given empiri-
cally? (Table 5 and Fig. 2)
Recommendations
1. All patients with suspected meningitis or meningo-
coccal sepsis should be given 2 g ceftriaxone intrave-
nously (IV) every 12-h or 2 g cefotaxime IV every 6-
h [1B]
2. If the patient has, within the last 6 months, been to a
country where penicillin resistant pneumococci are
prevalent, IV vancomycin 15e20 mg/kg should be
added 12-hourly (or 600 mg rifampicin 12-hourly IV or
orally) [1C]
Does the pa?ent have 
suspected meningi?s? 
Give Cefotaxime 2 g qds or 
Ce?riaxone 2g bd IV 
Does the pa?ent have anaphylaxis to penicillins or cephalosporins? 
No Yes
Give Chloramphenicol 
25mg/kg qds IV 
UK adult meningitis guidelines 4193. Those aged 60 or over should receive 2 g IV ampicillin/
amoxicillin 4-hourly in addition to a cephalosporin [1B].
4. Immunocompromised patients (including diabetics and
those with a history of alcohol misuse) should receive
2 g IV ampicillin/amoxicillin 4-hourly in addition to a
cephalosporin [1B].
5. If there is a clear history of anaphylaxis to penicillins or
cephalosporins give IV chloramphenicol 25 mg/kg 6-
hourly [1C]If the pa?ent has recently 
travelled abroad consider the 
possibility of an?microbial 
resistance:
See h?p://bit.ly/1rOb3cx  and  
h?p://bit.ly/1Kosckx for up to 
date informa?on. 
Please seek specialist infecƟon 
advice regarding anƟmicrobials 
in this situaƟon 
AND 
Dexamethasone 10mg qds IV 
AND 
Dexamethasone 10mg qds IV 
Is the pa?ent aged 60 or over? 
Yes 
Add in Amoxicillin 2g IV 4 
hourly 
Add in Co-trimoxazole 10-
20mg/kg (of the 
trimethoprim component) in 
four divided doses Is penicillin resistant 
pneumococci a possibility? 
Yes 
Add in Vancomycin 15-
20mg/kg bd  
OR 
Rifampicin 600mg bd 
Is the pa?ent aged 60 or over? 
Yes
Figure 2 Algorithm for the empirical treatment of suspected
meningitis.Rationale
The choice of antibiotics in patients with bacterial menin-
gitis is a three stage process, with initial empirical decisions
based on clinical suspicion, modified once CSF Gram stain is
available, and then again if CSF culture results are positive.
Antimicrobial penetration into the CSF is dependent on
lipid solubility, molecular size, capillary and choroid plexus
efflux pumps, protein binding, and the degree of inflam-
mation of the meninges.121 Although there is little high
quality trial evidence to guide the antibiotics used in sus-
pected meningitis and meningococcal sepsis the choice of
empirical antibiotic is based largely on known pharmacoki-
netics, the likely infecting organism and known or sus-
pected antimicrobial resistance patterns. Third
generation cephalosporins122 have known bactericidal ac-
tivity for both pneumococci and meningococci and pene-
trate inflamed meninges; as such they are the empirical
antibiotic of choice in most settings where resistance rates
are low.
Rates of pneumococcal resistance to penicillin in the UK
are low, but a travel history may indicate that a patient
with meningitis has recently been in a country with high
rates of pneumococcal resistance (Box 8). If a patient has
visited such a country in the last 6 months, then vancomy-
cin or rifampicin should be added to the empirical antibi-
otics. Up to date European and worldwide data on
resistance can be found via the European Centre for Disease
Prevention and Control website or the World Health Organi-
sation (http://bit.ly/1Kosckx and http://bit.ly/1rOb3cx).
Although meningococci with reduced susceptibility to peni-
cillin have been reported, patients infected by these strains
do respond to the high doses of penicillin or cephalosporinsTable 5 Empirical antibiotic choices.
Preferred choice
Adults <60 years of agea Cefotaxime 2 g 6 hourly
OR
Ceftriaxone 2 g 12 hourly
Adults 60 years of agea Cefotaxime 2 g 6 hourly
OR
Ceftriaxone 2 g 12 hourly
AND
Amoxicillin 2 g 4 hourly
a Add in IV Vancomycin 15e20 mg/kg bd or Rifampicin 600 mg bd if p
from a country where penicillin resistant pneumococci are prevalen
expertise).usually given in meningitis. Overt meningococcal resistance
to penicillin is extremely rare.13
Listeria meningitis occurs in people who are immuno-
compromised, have chronic illnesses such as alcohol depen-
dency, diabetes, and malignancy, or are elderly.123 It
responds poorly to cephalosporin treatment, and so amox-
icillin should be added. The age at which it should be added
is debated. Although in some guidelines a cut-off of 50Alternative
Chloramphenicol 25 mg/kg 6 hourly
Chloramphenicol 25 mg/kg 6 hourly
AND
Co-trimoxazole 10e20 mg/kg (of the
trimethoprim component) in four divided doses
enicillin resistance is suspected e.g. patient has recently arrived
t (if unsure, check with local infectious diseases/microbiology
Box 8. Selected countries with penicillin
resistance (refer to286 for a complete list).
Canada
China
Croatia
Greece
Italy
Mexico
Pakistan
Poland
Spain
Turkey
USA
420 F. McGill et al.years has been advocated,1,65 a review of the literature has
shown that Listeria meningitis or invasive Listeriosis in the
immunocompetent adult was rare if under 60.124e131
Although reactions to penicillin are commonly reported by
patients, a careful history should be taken as there is often
littleevidence for a trueallergy.Alternativeantibiotics should
be given only when there is a clear history of anaphylaxis to
penicillins or cephalosporins and the history of any alleged
allergic reactions should be investigated carefully.
What definitive antimicrobial treatment should be
given once microbiology results are available?
(Table 6)Recommendations
Patients with meningitis:
Treatment following CSF Gram stain result
6. If Gram-positive diplococci (likely Streptococcus pneu-
moniae) are visible on Gram stain of CSF:
B Continue 2 g ceftriaxone IV 12 hourly or 2 g cefo-
taxime IV 6-hourly (AR)
B If the patient comes from a country where peni-
cillin resistance is common add vancomycin
15e20 mg/kg IV 12-hourly (rifampicin 600 mg IV/
orally 12-hourly can be given as an alternative
and should be used in patients with renal failure)
until antimicrobial resistance information is avail-
able (AR)
7. If Gram-negative diplococci (likely N. meningitidis) are
visible on Gram stain of CSF:
B Continue 2 g ceftriaxone IV 12 hourly or 2 g cefo-
taxime IV 6-hourly (AR)
8. If Gram-positive bacilli suggestive of Listeria monocyto-
genes are visible on Gram stain of CSF:
B Add ampicillin/amoxicillin 2 g 4-hourly IV (if not
started empirically) (AR).
B Continue with 2 g ceftriaxone IV 12 hourly or 2 g
cefotaxime IV 6-hourly until culture confirmed
(AR).
9. If Gram negative rods are visible on Gram stain:B Continue 2 g ceftriaxone IV 12-hourly or 2 g cefo-
taxime IV 6-hourly and seek specialist advice
regarding local antimicrobial resistance patterns
(AR)
B If there is a high suspicion that an extended spec-
trum beta lactamase (ESBL) organism might be
present IV Meropenem 2 g 8 hourly should be given
(AR)
Treatment following positive culture or PCR result (from
blood or CSF):
Pneumococcal meningitis
10. If Streptococcus pneumoniae is identified:
B Continue with 2 g ceftriaxone IV 12 hourly or 2 g
cefotaxime IV 6-hourly (AR)
B If the pneumococcus is penicillin sensitive
(MIC 0.06 mg/L) any of the following options
would be suitable: IV benzylpenicillin 2.4 g 4 hour-
ly, 2 g ceftriaxone IV 12 hourly or 2 g cefotaxime IV
6-hourly (AR)
B If the pneumococcus is penicillin resistant
(MIC> 0.06) but cephalosporin sensitive then cefo-
taxime or ceftriaxone should be continued (AR)
B If the pneumococcus is both penicillin and cepha-
losporin resistant, continue using 2 g ceftriaxone
IV 12-hourly or 2 g cefotaxime IV 6-hourly plus van-
comycin 15e20 mg/kg IV 12-hourly plus 600 mg
rifampicin IV/orally 12-hourly (AR).
11. For patients with confirmed pneumococcal meningitis
who have recovered by day 10 treatment should be
stopped (1C).
12. For patients with confirmed pneumococcal meningitis
who have not recovered by day 10, 14 days treatment
should be given (1C)
13. For patients with penicillin or cephalosporin resistant
pneumococcal meningitis, treatment should be
continued for 14 days (1C)
Meningococcal meningitis
14. If N. meningitidis is identified:
B Continue 2 g ceftriaxone IV 12 hourly or 2 g cefo-
taxime IV 6-hourly (AR)
B 2.4 g benzylpenicillin IV 4-hourly may be given as
an alternative (AR)
B If the patient is not treated with ceftriaxone, a sin-
gle dose of 500 mg ciprofloxacin orally should also
be given (1C)
15. For patients with confirmed meningococcal meningitis
who have recovered by day 5 treatment can be stopped
(1C)
Other bacteria
16. If Listeria monocytogenes is identified:
B Give 2 g ampicillin/amoxicillin IV 4-hourly (stop Cef-
triaxone/Cefotaxime) and continue for at least 21
days (AR)
B Co-trimoxazole 10e20 mg/kg in four divided dose-
s(of the trimethoprim component) or
Table 6 Definitive antibiotic treatment.
Aetiology Antibiotic (s) Dose Alternative
antibiotic choices
Dose Durationb
Neisseria
meningitidis
Cefotaxime
OR
Ceftriaxone
2 g 6 hourly/2 g
12 hourly
Chloramphenicol
(if anaphylaxis) OR
Benzylpenicillin
25 mg/kg
6 hourly
2.4 g
4 hourly
5 days
Streptococcus
pneumoniae
(sensitivities
unknown or
penicillin
resistant,
cephalosporin
sensitive)
Cefotaximea
OR
Ceftriaxonea
2 g 6 hourly
2 g 12 hourly
Chloramphenicol 25 mg/kg
6 hourly
10 days (if stable)
Up to 14 days if
taking longer to
respond
Streptococcus
pneumoniae
(penicillin
sensitive,
MIC 0.06)
Benzylpeni
cillin
OR
Cefotaxime
OR
Ceftriaxonec
2.4 g 4 hourly
2 g 6 hourly/2 g
12 hourly
Chloramphenicol 25 mg/kg 6 hourly 10 days (if stable)
Up to 14 days if
taking longer to
respond
Streptococcus
pneumoniae
(penicillin and
cephalosporin
non-susceptible,
penicillin
MIC> 0.06 or
cefotaxime/
ceftriaxone
MIC> 0.5)
Cefotaxime
OR
Ceftriaxone
AND
Vancomycind
OR
Rifampicin
2 g 6 hourly
2 g 12 hourly
15e20 mg/kg
12 hourly
(adjusting
according to
serum trough
levels)
600 mg bd
Chloramphenicol 25 mg/kg
6 hourly
14 days
Listeria
monocytogenes
Amoxicillin 2 g 4 hourly Co-trimoxazole 10e20 mg/kg
(of the
trimethoprim
component) in
4 divided doses
21 days
Haemophilus
influenzae
Cefotaxime
OR
Ceftriaxone
2 g 6 hourly
2 g 12 hourly
Moxifloxacin 400 mg od 10 days
a Add in IV Vancomycin 15e20 mg/kg bd or Rifampicin 600 mg bd if penicillin resistance is suspected e.g. patient has recently arrived
from a country where penicillin resistant pneumococci is prevalent (if unsure, check with local infectious diseases/microbiology
expertise.
b Treatment durations may need to be extended if patient is not responding.
c If low risk of Clostridium difficile infection and/or requiring outpatient therapy.
d Serum vancomycin trough concentrations of 15e20 ug/ml should be aimed for.
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tives in cases of anaphylaxis to beta lactams (AR).
17. If H. influenzae is identified:
B Continue 2 g ceftriaxone IV 12-hourly or 2 g cefo-
taxime IV 6-hourly for 10 days (1D)
18. If a member of the Enterobacteriaceae is isolated from
blood or CSF:
B Continue 2 g ceftriaxone IV 12-hourly or 2 g
cefotaxime IV 6-hourly and seek specialist
advice regarding local antimicrobial resistance
patterns (AR)
B If there is a high suspicion that an extended spec-
trum beta lactamase (ESBL) organism might bepresent IV Meropenem 2 g 8 hourly should be given
(AR)
B Treatment should continue for 21 days (AR)
19. In patients with no identified pathogen who have recov-
ered by day 10 treatment can be discontinued (AR)Patients with probable/confirmed meningococcal sepsis
(no lumbar puncture):
20. Patients with confirmed meningococcal sepsis:
B Continue 2 g IV ceftriaxone every 12 h or 2 g cefo-
taxime IV 6-hourly (AR)
422 F. McGill et al.B 2.4 g benzylpenicillin IV 4-hourly may be given as
an alternative (AR)
B For patients who have recovered by day 5, treat-
ment can be discontinued (1C).
21. For patients with a typical petechial/purpuric meningo-
coccal rash but no identified pathogen who have been
treated as above, and recovered by day 5, treatment
can be stopped (1C).
22. In patients with confirmed or probable meningococcal
sepsis who have not been treated with ceftriaxone, a
single dose of 500 mg ciprofloxacin orally should also
be given (1C)All patients
23. Outpatient intravenous therapy should be considered in
patients who are clinically well (AR)Rationale
Definitive antibiotic choices are based on the organism
identified (or likely organism) and its antimicrobial suscep-
tibilities. As cephalosporins are recommended for empirical
treatment, we recommend their continued use for patients
found to have meningococcal or pneumococcal disease,
although we recognise that some centres will prefer to
narrow the spectrum and use benzylpenicillin for patients
with a susceptible organism. Previously gentamicin has
been advocated for its synergistic activities in listeria
meningitis but its use is not supported by recent
studies.127,132 Vancomycin is recommended for penicillin
resistance but it should never be used alone as there are
doubts about its penetration into adult CSF, especially if
dexamethasone has also been given.133 A trough vancomy-
cin level of 15e20 mg/L should be aimed for. It is widely
accepted that this trough range should be aimed for in
serious infection. Most of the evidence is in patients with
staphylococcal infection and in patients with bacteraemia
or pneumonia, but has been extrapolated to other infec-
tions.134 Some experts also recommend repeating the lum-
bar puncture after 48e72 h of therapy in patients who have
a penicillin and cephalosporin resistant pneumococcus. This
should be discussed with an infection specialist on a case by
case basis.
No beta-lactams other than ceftriaxone have been
shown to reliably eradicate meningococcal carriage in the
oropharynx. Therefore a single dose of Ciprofloxacin should
be given to eliminate throat carriage to all patients in
whom meningococcal disease is confirmed or strongly
suspected, who have been treated with an antibiotic other
than ceftriaxone (including those treated with cefotaxime).
If ciprofloxacin is contraindicated rifampicin 600 mg twice
daily for two days can be given as an alternative.
Meningitis caused by gram negative bacilli is rare,
although incidence may be increasing.7,135 In addition
multidrug resistance such as extended spectrum beta lacta-
mases (ESBLs) enterobacteriaciae is increasing. ESBL should
be considered in patients who have Gram negative bacilli in
the CSF or on blood culture and have recently returnedfrom a country or area of high prevalence, or who have
an ESBL cultured from other sites e.g. urine.
Duration of treatment
There is little evidence to guide the duration of treatment
in adults. The recommendations here have been extrapo-
lated from the paediatric literature. The duration of
antibiotic therapy depends upon which pathogen is identi-
fied. The management of epidemic meningococcal menin-
gitis in Africa with a single dose of ceftriaxone has been
evaluated52 and compared well with earlier studies of sin-
gle doses of combined penicillins or depot chloramphen-
icol.136 Short courses of penicillin (3 days) have been
advocated for treatment of uncomplicated adult meningo-
coccal meningitis in New Zealand but have not been evalu-
ated in controlled, prospective studies.137 A meta-analysis
found no difference between short (4e7 days) versus long
(7e14 days) courses of antibiotics for all causes of bacterial
meningitis.138 However, no trials in adults were identified
for inclusion. In a subsequent double-blind randomised
equivalence study conducted in Bangladesh, Egypt, Malawi,
Pakistan, and Vietnam, it was concluded that antibiotics
can be safely discontinued in children who are stable by
day 5 of ceftriaxone treatment.139
We recommended that if the patient is judged clinically
to have recovered by 10 days for pneumococcal disease and
5 days for meningococcal disease the antibiotics can be
stopped. In addition, if no pathogen has been found
antibiotics can be stopped after 10 days if the patient has
clinically recovered.
Alternative antibiotic therapy approaches
Alternative antibiotics may be useful in cases of allergy, or
increased antimicrobial resistance. Carbapenems have a
broad range of activity against Gram-positive and Gram-
negative bacteria. Controlled trials in children and a small
number of adults, suggest that meropenem has similar
efficacy to cefotaxime or ceftriaxone in the treatment of
bacterial meningitis140 and may be useful in the future. Ga-
tifloxacin and moxifloxacin penetrate the CSF well and
experimental models support their potential role in the
treatment of penicillin and cephalosporin-resistant menin-
gitis,141,142 however there is concern regarding the rapid
emergence of resistance with fluoroquinolone treat-
ment.143 Intraventricular antimicrobial agents have been
shown to be of use in nosocomial meningitis associated
with extra ventricular drains,144but are not indicated in
the management of adult community acquired bacterial
meningitis. There is some evidence from animal models of
pneumococcal meningitis that compared with ceftriaxone,
antibiotics such as daptomycin and rifampicin sterilise the
CSF more rapidly, modulate CSF inflammation, and protect
against cortical injury.145,146 However, until there are hu-
man trials to support the use of these antibiotics they
cannot be recommended as an alternative to
cephalosporins.
Outpatient antibiotic therapy
Outpatient antibiotic therapy (OPAT) is increasingly being
used for many different infections including meningi-
tis.147e150 Outpatient therapy has cost savings by freeing
up hospital beds and there may be psychological benefits
Box 9. Outpatient therapy (OPAT) of meningitis and meningococcal disease.
7a. Indications where outpatient therapy may be appropriate
 The decision to commence OPAT must be made by a physician familiar with OPAT and should be carried out by a specialist OPAT
team and include regular review of cases by a physician
 The patient should:
B be afebrile and clinically improving
B have received 5 days of inpatient therapy and monitoring (?shorter)
B have reliable intravenous access
B be able to access medical advice/care from the OPAT team or delegated individuals 24 h a day
B have no other acute medical needs other than the need for parenteral antimicrobials
 The patient and family/carer must be willing to participate in OPAT
7b. Regimes that could be used in the community
 Ceftriaxone 2 g bd IV (4 g od IV can be used after the first 24 h of therapy)
 Ceftriaxone 2 g bd IV and Rifampicin 600 mg bd PO for penicillin resistant pneumococci
UK adult meningitis guidelines 423for the patient treated in their own home.151,152 Some indi-
cations for when OPAT may be appropriate and what regi-
mens might be considered are given in Box 9.
There is concern regarding once daily cephalosporins in
meningitis and the risk of having sub-therapeutic levels.
Animal studies have shown that once daily ceftriaxone
achieves similar CSF sterilisation rates as twice daily after
the first 24 h153 and a small clinical study, with no compar-
ator arm, showed once daily ceftriaxone achieved effective
CSF concentrations and sterilised the CSF within
24e48 h.154 In the first 24 h cephalosporins should be given
twice a day to achieve rapid CSF sterilisation, thereafter
they can be given once daily to patients who have recov-
ered sufficiently to be considered for OPAT.
Which adjunctive treatment should be given?
Recommendations
For patients with suspected meningitis:
24. 10 mg dexamethasone IV 6 hourly should be started on
admission, either shortly before or simultaneously with
antibiotics [1A].
25. If antibiotics have already been commenced 10 mg IV
dexamethasone every 6 h should still be initiated, up
until 12 h after the first dose of antibiotics (AR).
26. If pneumococcal meningitis is confirmed, or thought
probable based on clinical, epidemiological and CSF pa-
rameters, dexamethasone should be continued for 4
days [1C].
27. If another cause of meningitis is confirmed, or thought
probable, the dexamethasone should be stopped (1C).
28. Glycerol is not recommended as adjuvant therapy for
community acquired bacterial meningitis in adults [1B].
29. Therapeutic hypothermia is not recommended for
adults with bacterial meningitis [1B]Rationale
Over 10% of adults with bacterial meningitis die, even when
appropriate antibiotics are started promptly, and it is likelythat major further improvements in outcome will not come
from changes in antibiotic therapy but from manipulation
of the host responses to infection or with the development
of alternatives to antibiotics, such as engineered liposomes
e still in early animal trials.155The role of corticosteroids in community acquired
bacterial meningitis
Corticosteroids have many potential anti-inflammatory
effects in bacterial meningitis including decreasing the
amount of cytokines released, for example, through inhib-
iting the transcription of mRNA for TNF-a and IL-1156e160
and inhibition of the production of prostaglandins and
platelet activating factor.161 Methylprednisolone decreases
meningeal inflammation in a rabbit model of pneumococcal
meningitis,162 decreases CSF outflow resistance163 and re-
duces cerebral oedema.164 Dexamethasone plus ceftriax-
one when given in a rabbit model of H. influenzae
meningitis resulted in significantly reduced CSF TNF-a con-
centration and a reduced CSF white cell count.160 In these
animal models the improvement in outcome only occurred
when dexamethasone was given before or with the
antibiotics.160
On the other hand corticosteroids may be associated
with side effects. In experimental models the administra-
tion of corticosteroids reduced the penetration of antibi-
otics into the CSF,133 although this has not been born out in
small studies conducted in humans.165e167 Animal studies
also suggest that corticosteroids can aggravate the cogni-
tive deficits that may occur after bacterial meningitis.168
Trials of corticosteroids in man have shown conflicting re-
sults regarding overall benefit. Controlled trials in children
showed some benefit in reducing deafness and neurological
deficit, largely in meningitis caused by H. influenzae. Dexa-
methasone, given before or with the first dose of antibiotics
in adults, improved outcome, particularly in those with
pneumococcal meningitis, in a Dutch trial.169 In contrast,
20 years of experience in Croatia and randomised
controlled trials of adult meningitis in Malawi and Vietnam
did not show any benefits overall.170e172 Two systematic re-
views and one meta-analysis (including four studies from
1999 to 2007) suggested that adjunctive corticosteroids
are beneficial in adults with bacterial meningitis in high-
424 F. McGill et al.income countries.173e175 However, a subsequent meta-
analysis of individual patient data from trials amongst chil-
dren and adults in resource-rich and poor settings showed
no benefit.176 This analysis is confounded, however, by
considerable heterogeneity between the trials analysed.
The most recent Cochrane review concluded there was a
small reduction in mortality for patients with pneumo-
coccal meningitis who received corticosteroid therapy, but
not other causes. There was also a reduction in hearing loss
and short term neurological sequelae for all causes.173 Data
from this review and a meta-analysis of individual patient
data showed no difference in outcome when comparing cor-
ticosteroids that were given before or after antibiotics,176
there was even a slight improvement in hearing loss in
the studies that gave steroids post antibiotics.173 The
data so far do not show any increase in adverse events,
such as increased cognitive deficits or gastrointestinal
bleeding.173,177,178 A potential rare complication of dexa-
methasone therapy in pneumococcal meningitis is delayed
cerebral thrombosis179,180 although a causal relationship
between this complication and dexamethasone has not
yet been established.
Given that there is no evidence for harm in giving
corticosteroids, and that some groups do appear to benefit,
we recommend that for adults in whom bacterial meningitis
is suspected, dexamethasone be given before, or up to 12 h
after, antibiotics are started. Steroids should be then
stopped, if a cause, other than Streptococcus pneumoniae
is identified. If no cause is found and pneumococcal menin-
gitis remains most likely based on clinical, epidemiological
and CSF parameters, the steroids should be continued for 4
days.
Whilst high dose steroids are used in meningitis to
reduce brain inflammation and oedema, low dose hydro-
cortisone is occasionally used in septic shock to restore
haemodynamic stability. Recommendations on when hydro-
cortisone would be appropriate in septic shock can be
found below and in the surviving sepsis guidelines.41Adjunctive therapy with glycerol in community acquired
bacterial meningitis
Glycerol is a hyperosmolar agent that has been used to
decrease intracranial pressure in a number of brain condi-
tions. A randomised clinical trial in Finland suggested that
glycerol might protect against sequelae in children with
bacterial meningitis.181 However, a subsequent South
American trial showed no significant benefit of adjuvant
intravenous dexamethasone, oral glycerol, or both on death
or deafness but there was a reduction in neurological
sequelae in both the glycerol alone group and those who
received dexamethasone and glycerol.182 Later randomised
trials in Malawi found an increase in mortality in adults
treated with glycerol and no benefit in children.183,184Other therapeutic approaches
Animal models and individual patient data suggested a
potential benefit of induced hypothermia in bacterial
meningitis.185,186 However a recent randomised controlled
trial was stopped prematurely because of excess mortality
in the hypothermia arm.187Critical care
Which patients with suspected or confirmed meningi-
tis should be referred for critical care?
Recommendations
1. Intensive care teams should be involved early in pa-
tients with rapidly evolving rash, evidence of limb
ischaemia, cardiovascular instability, acid/base distur-
bance, hypoxia, respiratory compromise, frequent sei-
zures or altered mental state (1B).
2. The following patients should be transferred to critical
care (1B):
a. Those with a rapidly evolving rash
b. Those with a GCS of 12 or less (or a drop of >2
points)
c. Those requiring monitoring or specific organ support
d. Those with uncontrolled seizures
3. Intubation should be strongly considered in those with a
GCS of less than 12 (AR)
4. Patients with evidence of severe sepsis should be
managed in a critical care setting in accordance with
the surviving sepsis guidelines (AR).Rationale
Given the predisposition of patients with bacterial menin-
gitis and meningococcal sepsis to deteriorate quickly, and
the high mortality rate, critical care input should be sought
early in patients with risk factors for a poor outcome,
especially a reduced GCS, haemodynamic instability,
persistent seizures, and hypoxia.188 Patients with meningo-
coccal sepsis are typically young adults, who tend to main-
tain their blood pressure until late in disease, and then
deteriorate rapidly. Patients should be examined for other
signs of cardiac instability and impaired perfusion for
example delayed capillary refill time, and dusky or cold
extremities.
What other critical care management issues are
important?
Recommendations
5. Patients should be kept euvolaemic to maintain normal
haemodynamic parameters (2C)
6. Fluid restriction in an attempt to reduce cerebral
oedema is not recommended (2C)
7. When intravenous fluid therapy is required, crystalloids
are the initial fluid of choice (1B)
8. Albumin should be considered in patients who have
persistent hypotensive shock in spite of corrective
measures (1C)
9. Patients with suspected or proven raised intracranial
pressure should receive basic measures to control this
and maintain cerebral perfusion pressure (1C)
10. Routine use of ICP monitoring is not recommended (AR)
11. Hydrocortisone (200 mg od) should also be considered
in patients with persisting hypotensive shock (2C)
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ommended; although this may need to be individual-
ised (1B)
13. Use norepinephrine as opposed to epinephrine or vaso-
pressin as the initial vasopressor for hypotension after
euvolaemia is restored (1B)
14. Suspected or proven seizures should be treated early
(1C).
15. Patients with suspected or proven status epilepticus
(including non-convulsive/subtle motor status), such
as those with fluctuating GCS off sedation or subtle
abnormal movements, should have electroencephalo-
gram monitoring (AR)
Evidence
Adult patients with bacterial meningitis and meningococcal
sepsis have differing needs for intravenous fluid therapy.
Some patients, such as those with primarily meningitis and
little evidence of sepsis, are relatively euvolaemic,
whereas others have profound or occult shock requiring
early restoration of circulating volume. Over-vigorous
administration of intravenous fluids in patients with men-
ingitis may risk exacerbation of cerebral oedema, but
paediatric meningitis studies have shown that fluid restric-
tion may also contribute to a worse outcome.189,190 Conse-
quently, the management of meningitis should target the
maintenance of a normal circulating volume avoiding both
under and over-hydration and the associated adverse
outcomes.
In patients with meningitis, control of raised intracranial
pressure is also essential to prevent mortality although it is
still not clear how best to achieve this and there is not
sufficient evidence to support the routine use of ICP
monitoring.31,191 Measures such as achievement of normal
to elevated MAP, control of venous pressure, head eleva-
tion, avoidance of hyperthermia and hyponatraemia and
maintenance of normocarbia and normoglycaemia may be
considered.192
Seizures have been reported to occur in 15% of patients
with acute bacterial meningitis and are associated with a
worse outcome,9 therefore anticonvulsant treatment
should be started promptly even when seizures are sus-
pected but not proven.193 Patients with suspected or
proven status epilepticus should also have EEG
monitoring.
The aim of fluid replacement in meningococcal sepsis is
to reverse shock, as shown by normalisation of lactate
levels and maintenance of urine output at >/Z0.5 ml/kg/
h. The type of fluid to be given, in all types of sepsis, has
been debated but in general it seems that albumin does not
have any survival benefit over crystalloids alone.194In a sub-
group analysis of this study, albumin was associated with
some improvement in survival and a shorter duration of va-
sopressors in those with more severe sepsis, where shock
was also present. Albumin should be considered in patients
with sepsis who have worsening shock and require signifi-
cant amounts of fluid resuscitation.
Although the WaterhouseeFriderichsen syndrome with
adrenal failure is very rare, there is some evidence that
refractory septic shock may be more common in patientswith impaired adrenal responsiveness.195,196 Low-dose, ste-
roid supplementation may improve survival in those with
refractory septic shock and documented adrenal hypo
responsiveness.197 Hydrocortisone, at a dose of 200 mg
once a day, should be given in cases of resistant shock.41
A MAP of 65 mmHg is the target for most patients although
this will need to be individualised in specific cases; in a
younger patient with significant shock, dusky looking digits
and minimal cerebral oedema, a lower MAP (such as
50e60 mmHg) may be acceptable, whereas, in an older pa-
tient with evidence of cerebral oedema a higher MAP (such
as 70 mmHg), and hence cerebral perfusion pressure, may
be desirable. Norepinephrine is the vasopressor of choice
given that it has equivalent efficacy to dopamine but less
adverse events.198 Vasoactive agents such as norepineph-
rine should be initiated early in persistent shock, via a cen-
tral vein. Dilute concentrations of these agents can be
given through a peripheral vein until central access is es-
tablished. A low-dose of glyceryl trinitrate (1e2 mg/h)
may be useful in those patients with progressive shock
and ischaemic digits.
Meningococcal sepsis is frequently associated with a
procoagulant state, with the attendant risk of the develop-
mentofmicrothrombiwithin theperipheral circulation.Over
the last few decades it has been shown that these patients
are often deficient in protein C, protein S, and antithrombin
III,199e201 have a defective endothelial protein C activation
pathway202 and have both low and dysfunctional
platelets.203e205 Patients with bleeding and overt DIC (indi-
cated by low platelets, low fibrinogen and elevated clotting
times) should be treated according to established manage-
ment guidelines.206 Blood products may also be used to cor-
rect anaemia, thrombocytopenia and coagulopathy in
consultation with local haematology teams.Prevention
What measures should be taken to prevent secondary
cases?Recommendations
1. All cases of meningitis (regardless of aetiology) should
be notified to the relevant public health authority (AR).
2. The Consultant in Communicable Disease Control
(CCDC) or Consultant in health protection in the Public
Health England health protection team should be con-
tacted early (AR).
3. Prophylaxis of contacts should be initiated by the
CCDC/Consultant in health protection and not the
admitting clinicians (AR).
Rationale
Meningitis and meningococcal sepsis are notifiable diseases
in the UK.207e209 There is a legal obligation to ensure the
relevant public health authority is aware of all cases. Any
prophylaxis of contacts should be instigated by the public
health team, although in some instances the clinical team
may be asked to arrange the prescription.210
426 F. McGill et al.Meningococcal infection
Recommendations
4. Ciprofloxacin should be given to all close contacts of
probable or confirmed meningococcal meningitis (1C)
B 500 mg stat for adult contacts
B 250 mg stat for child contacts aged 5e12 years
B 30 mg/kg up to a maximum of 125 mg stat for child
contacts under 5 years
5. In those unable to take Ciprofloxacin, Rifampicin can be
given as an alternative (1C).
B 600 mg twice a day for 2 days for contacts over the
age of 12
B 10 mg/kg twice a day for 2 days for contacts aged
1e12 years
B 5 mg/kg twice a day for 2 days for contacts aged
less than 12 months
6. Vaccine can be given to any unvaccinated contacts of
cases caused by any non-B serogroup(1C)
7. If 2 or more cases of serogroup B disease occur within
the same family vaccination against serogroup B should
be offered to all household contacts (AR)
In addition to prophylaxis to contacts the following should
also be offered to the index case:
8. Any unimmunised index case under the age of 25 years
(whatever the capsular serogroup) should be offered
vaccination according to the national schedule (currently
monovalent MenC at 3months, combined Hib/MenC at 12
months and MenACWY vaccine at 13/14 years) (1D)
9. Cases of confirmed serogroup C disease who are eligible
for vaccination and have previously been immunised
with Meningococcal C conjugate (or polysaccharide)
vaccines should be offered a booster dose of Meningo-
coccal C conjugate vaccine around the time of
discharge from hospital (1D)
10. If two or more cases of probable/confirmed IMD due to
the same vaccine preventable strain in the same educa-
tional or residential setting within a four week period
occur then wider vaccination may be offered in line
with national guidance211 (AR)
Rationale
Although 10% of the population may carry meningococci
asymptomatically at anyone time, carriage rates are age
dependent. Less than 2% of children aged under 5 years and
20e25% of older teenagers and young adults carry the
meningococcus.212 Secondary attack rates are approxi-
mately 2e4 per 1000 population in close contacts of cases;
a 1000-fold increase above the overall reported attack rate
of meningococcal disease in adults (0.23/100,000).
Most patients with systemic disease have acquired the
invading meningococcus within the previous 7 days and
secondary prevention targets household contacts within the
previous week. Other close contacts would include ‘inti-
mate kissing contacts’. For antibiotic prophylaxis, the use
of single dose ciprofloxacin is now recommended in pref-
erence to rifampicin in all age groups and in pregnancy,
particularly because it is a single dose and is readily
available in high street pharmacies. Ceftriaxone as a single
dose or Rifampicin given over two days are alternatives.210Regardless of the use of prophylaxis an extra risk persists
for at least 6 months in contacts of patients with invasive
infection. The general practice records of all close contacts
of meningococcal disease should be labelled to alert
doctors that an increased risk of meningococcal disease
persists for 6 months. Contacts of cases of disease caused
by vaccine preventable non-B serogroups should be offered
vaccination.213
After a second confirmed serogroup B case occurs in a
household, meningococcal serogroup B vaccination
(Bexsero) should be considered in addition to chemopro-
phylaxis for all household contacts, even if the interval be-
tween the two cases is >30 days and/or the serogroup B
strains are subsequently identified to be different.214
H. influenzae type b infection
Recommendations
1. Where H. influenzae type B is confirmed as the cause
the index case and all household contacts, in house-
holds which contain an at risk individual, should receive
prophylactic Rifampicin (20 mg/kg to a maximum of
600 mg, once daily for 4 days), this should normally
by initiated by the appropriate health protection
team following notification (1C)
2. Vaccination should be given to all previously unvacci-
nated household contacts, under the age of 10 (1C)
Rationale
H. influenzae meningitis is uncommon in adults but if infec-
tion is caused by a type b strain then it should be confirmed
that all children aged up to 10 years among household con-
tacts have received H. influenzae type b (Hib) vaccination;
household contacts are defined as any individual who has
had prolonged close contact with the index case in a
household-type setting during the seven days before the
onset of illness. Children younger than 10 years who have
never been immunised against Hib should receive vaccina-
tion according to recommendations given in the ‘green
book’.213 In a household where there is an at risk individual
(a child under 10 or a vulnerable individual of any age such
as the immunosuppressed) all household contacts and the
index case should be given rifampicin 20 mg/kg once a
day (maximum of 600 mg) for 4 days for adults and children
older than 3 months. Infants younger than 3 months should
receive 10 mg/kg once a day for 4 days.
Pneumococcal meningitis
Close contacts of pneumococcalmeningitis are not usually at
an increased risk of pneumococcal infection and antibiotic
prophylaxis is not indicated. Clusters of invasive pneumo-
coccal disease occurring in elderly care homes, for example,
should be discussed with local health protection authority.
Screening for predisposing factors to meningitis or
meningococcal sepsis
Recommendations
3. All patients with meningitis should have an HIV test (1C)
4. Patients with a single episode of meningitis or meningo-
coccal sepsis should not be screened for any other
UK adult meningitis guidelines 427immunological deficiency unless there was some other
indication (1C)
5. All patients with two or more episodes of meningo-
coccal or pneumococcal meningitis should have appro-
priate immunological investigations (1B)
6. All patients who have a family history of more than one
episode of meningococcal disease should have appro-
priate immunological studies (1C)
7. Patients with either a history of trauma or recent
neurosurgery or evidence of rhinorrhea or otorrhoea
should have investigations for a CSF leak (AR).Rationale
HIV and meningitis
HIV can cause meningitis either directly or indirectly via
opportunistic infections. Meningitis caused by HIV itself
most often occurs during acute HIV infection but can occur
in established infection.215e217 Up to 24% of patients with
acute HIV infection may present with meningitis as part
of a seroconversion illness.218e220 Headache and fever are
common and there are often also other symptoms or signs
such as lymphadenopathy, oral candidiasis or rash.215,221
The prevalence of HIV in culture negative meningitis has
been reported between 1 and 5% in German and US co-
horts.19,222 Pneumococcal and meningococcal meningitis
have both been reported to have a higher incidence and a
higher mortality in HIV positive than HIV negative pa-
tients.217,223 HIV should therefore also be included in the
differential diagnosis in all cases of meningitis.224 During
the early phase of seroconversion illness, HIV antibody tests
may be negative. Many centres now have combined assays
for HIV antibody and p24 antigen (4th generation assays).
If there is a strong suspicion but the test is negative then
consider performing an HIV RNA PCR.
If a patient lacks capacity to consent and in the absence
of a power of attorney or advance directive, an HIV test
should be performed if it is deemed to be in the patient’s
best interests (England and Wales) or of benefit to the
patient (Scotland). Further information can be found in the
British HIV Association guidance on HIV testing.225
Other predisposing conditions
Any case of pneumococcal meningitis (confirmed or prob-
able) should prompt a review of the patient’s medical
history to establish whether they are in a recognised risk
group213 and whether they have been appropriately immu-
nised. Adults with asplenia or splenic dysfunction may be at
increased risk of invasive pneumococcal infection. Such in-
dividuals, irrespective of age or interval from splenectomy,
may have a sub-optimal response to the vaccine. Adults
with complement deficiency, or on Eculizumab (Soliris)
therapy, are at increased risk of invasive meningococcal
infection, and as such should be vaccinated and take pro-
phylactic antibiotics. A clinical immunologist should deter-
mine what investigations would be appropriate in cases of
recurrent meningitis or in cases where there is a family his-
tory of meningococcal disease.
A CSF leak due to disruption of the meninges, which may
be spontaneous, traumatic or iatrogenic, is a rare cause of
bacterial meningitis and may be recurrent. In patients with
recognised features such as rhinorrhoea or otorrhoea or riskfactors such as trauma or neurosurgery, investigations to
identify the source of leak, including CT and/or MRI are
warranted.226,227
What are the appropriate infection control
measures?
Recommendations
8. All patients with suspected meningitis or meningo-
coccal sepsis should be respiratory isolated and until
meningococcal meningitis or sepsis is excluded, or
thought unlikely, or they have received 24 h of Ceftriax-
one or a single dose of Ciprofloxacin (1C)
9. All patients with confirmed meningococcal meningitis
or meningococcal sepsis should be isolated and barrier
nursed until they have received 24 h of IV Ceftriaxone
or had a single dose of oral ciprofloxacin (or 48 h of
Rifampicin) (1C)
10. Droplet precautions should be taken until a patient has
had 24 h of antibiotics. This includes the wearing of sur-
gical masks if likely to be in close contact with respira-
tory secretions or droplets (2C)
11. Antibiotic chemoprophylaxis should be given to health-
care workers who have been in close contact with a pa-
tient with confirmed meningococcal disease ONLY when
exposed to their respiratory secretions or droplets for
example during intubation or as part of CPR when a
mask was not worn (1C)Other causes of meningitis do not require isolation
Rationale
Suspected meningitis is one of the commonest occupational
exposures for healthcare workers,228 although healthcare
associated infection is extremely rare.229 The estimated
risk is 25 times greater than that of the general population
although lower than that of household contacts.229 Droplet
precautions are recommended until a patient has had 24 h
of effective antibiotic therapy. These precautions include
nursing the patient in a single room, surgical masks to be
worn by all if in close contact (<3 feet) with the patient,
and other standard infection prevention precautions.230
Antibiotic prophylaxis is only required for those whose
mouth or nose has come into close contact with the pa-
tients respiratory secretions. This is likely to be those
who are involved in airway management without wearing
a mask.
Follow up and sequelae
What follow up should be arranged and what sequelae
should be considered?
Recommendations
1. All patients should be assessed for potential long-term
sequelae, both physical and psychological before
discharge from hospital (AR).
2. The following sequelae should documented if present
(AR):
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dizziness and tinnitus
B Other neurological injury resulting in
- cognitive deficits and learning impairment
- epilepsy
- movement disorders
- visual disturbances
- other communication problems
B wounds, tissue damage and skin scars
B amputations and other orthopaedic sequelae
B psychiatric and psycho-social problems
B renal impairment
3. For patients receiving treatment in a critical care
setting at any point in their illness, assessment and
rehabilitation should conform to the NICE guidelines
on rehabilitation after critical illness (AR)
4 Hearing tests
a. Patients (including those who have had meningo-
coccal sepsis) should have a hearing test if the
clinician, the patient or their family thinks hear-
ing may have been affected, or if the patient no
longer has the capacity to report hearing loss
(AR).
b. The hearing test should take place before discharge
or within 4 weeks of being well enough to test,
whichever is sooner (AR).
c. The hearing test should be carried out by a hospital
based specialist (AR).
d. Patients found to have severe to profound deafness
should be offered a ‘fast-track’ assessment for
cochlear implant (AR).
5. All patients with confirmed or probable bacterial men-
ingitis should be given a medical follow up appointment
within 6 weeks after discharge (AR).
6. For patients with rehabilitation needs a rehabilitation
plan should be agreed with the patient, and their fam-
ily/carers (AR)Box 10. Complications of acute meningitis and m
Complication Warning
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New neu
Seizures (generalised
tonic-clonic or subtle motor)
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Reduced
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thrombosis
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Failure t
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Septic shock Cold per
Refracto
EEG e Electroencephalogram; MR e Magnetic resonance.7. All patients and their families should be provided with
the contact details of support organisations such as
the Meningitis Research Foundation (www.meningitis.
org) or Meningitis Now (www.meningitisnow.org) (AR).Rationale
Bacterial meningitis and meningococcal disease can cause a
variety of disabling sequelae resulting from either direct
neurological injury, or from damage secondary to sepsis.
Sequelae are more common following pneumococcal men-
ingitis, and occur in about 30% of such patients compared to
7% with meningococcal meningitis.9,231 The frequency of
sequelae is much higher in meningococcal sepsis (up to
57%).232,233 Some sequelae only become apparent after
the acute phase of the illness.177,234 Physical and psycho-
logical sequelae can have profound effects on both the pa-
tient and their family.235 Some of the more urgent
complications are shown in Box 10.
A prompt hearing assessment is essential in any patient
reporting hearing loss. Cochlear ossification can progress
rapidly and if not picked up early the success of cochlear
implant surgery is jeopardised. This problem has been well
described in children236 but also occurs in adults.237
Although initial hearing loss may subsequently recover
post-meningitis, this should not delay a timely audiological
review in the first instance. If a test is carried out early on
and the result shows hearing within the normal range, then
no further tests would be indicated. However, if the first
test shows a hearing loss, this would be followed up by sub-
sequent tests to review the situation after a period of time.
Neurological damage can be severe and plainly evident,
or may result in more subtle cognitive sequelae.177 The
injury can cause deficits in many different domains. Where
there is concern, patients should have access to neuropsy-
chological and neurological assessment,238 which can helpeningococcal sepsis.
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l movements
consciousness
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consciousness
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recovery.
Life-altering sequelae, or prolonged hospitalisation can
have profound psychological impacts, as described in the
NICE guidelines, ‘Rehabilitation after Critical Illness’.239
Emotional and psychological difficulties are well docu-
mented after acquired brain injury.240 Clinicians should
consider the need for early referral to mental health ser-
vices. Scarring and amputation due to meningococcal sepsis
creates particular problems with adjustment to altered
appearance,241,242 and early psychological assessment and
treatment are beneficial.243
Longer term, meningitis and sepsis can result in arthritis,
limb pain, muscle pain and neuropathic pain. Headaches
are frequently reported, occurring in up to one third of
patients.244
In theUK, the support, information andadvocacy provided
by support organisations such as the Meningitis Research
Foundation (www.meningitis.org) or Meningitis Now (www.
meningitisnow.org) can provide crucial help with this.
Many patients feel well at discharge from hospital and
do not realise that they may not be able to return to all
their normal duties and activities immediately. Fatigue,
sleep disorders, and emotional difficulties are frequently
reported in the weeks and months after discharge.245 Sup-
port from hospital clinicians and GPs can help with this
and enable patients to stage their return to work or studies
on a part-time basis initially.
Follow-up care is important, and several studies have
shown that it is not routinely offered where it is needed. In
a study of adolescents with meningococcal disease,233 only
half were offered any post-discharge follow up care. Post-
hospital follow up should be offered to all with confirmed
or probable bacterial meningitis because many issues will
only become apparent after discharge.
Viral meningitis
Recommendations
1. If viral meningitis is suspected on clinical, epidemiolog-
ical and CSF grounds:
B the CSF should be tested for enteroviruses, herpes
simplex viruses type 1 and 2 (HSV-1 and HSV-2) and
varicella zoster virus (VZV) by PCR (1C)
B PCR testing of CSF, or serological assays, for other
viruses should be guided by additional features in
the history and examination, e.g. immune compro-
mise and travel history (1C)
B Stool and/or throat swabs should be tested for
enterovirus by PCR (1C)
2. Aciclovir/Valaciclovir should not be given as prophy-
laxis for recurrent herpes meningitis (HSV or VZV) (2B)
Background and rationale
Since the first edition of these guidelines (1999) the relative
importance of viral meningitis has grown. This has been in
part due to the reduction in bacterial meningitis5,129 and in
part due to the increased frequency with which viral men-
ingitis is diagnosed, following more widespread use of mo-
lecular diagnostic technologies.246Viral meningitis is often considered to be a self-limiting,
benign illness247,248 and although it is rarely fatal in immu-
nocompetent adults, it can cause significant morbidity, and
may be responsible for underappreciated
sequelae.245,249,250 Viral meningitis is characterised by
inflammation of the meninges, in contrast viral encephalitis
is infection and inflammation of the brain parenchyma it-
self. Encephalitis is associated with different pathogens
and has a considerably worse prognosis.251,252 It is charac-
terised by changed behaviour, confusion or coma as
opposed to headache and neck stiffness ethe predominant
features in viral meningitis. There are recently published
guidelines on the management of viral encephalitis64,253
and although viral meningitis and encephalitis may be
differentiated clinically, if there is doubt, patients should
be managed as suspected encephalitis. In addition, distin-
guishing viral meningitis from bacterial meningitis is crucial
because of the different treatment, and outcomes.15,254
Epidemiology
The precise incidence of viral meningitis, particularly in
adults, is unknown but is estimated to account for at least
50% of the total meningitis burden and possibly up to
80%.8,15,27,255 As with bacterial meningitis it is probably
under-diagnosed and under-reported.256 In the UK, the
commonest viruses that cause meningitis are the enterovi-
ruses and the herpes viruses (predominantly HSV-2 and
VZV). There are over 90 enterovirus serotypes and it is
transmitted via the faecal-oral route. HSV-2 is a sexually
transmitted disease and VZV is transmitted primarily via
the respiratory route. Both VZV and HSV-2 meningitis can
occur with primary infection or as reactivation of disease.
Other less common aetiologies include cytomegalovirus,
EpsteineBarr virus and mumps virus e all of which should
be considered if initial tests do not reveal a cause. HSV-1 is
more commonly associated with encephalitis than
meningitis.18
Clinical features
Patients with viral meningitis present with meningism (neck
stiffness, headache and photophobia). Fever is not always
present. Other non-specific symptoms such as diarrhoea,
vomiting, muscle pain, and sore throat are sometimes
seen.257 Patients with HSV-2 meningitis rarely have concur-
rent genital ulcers caused by the virus and often don’t have
any history of genital disease. VZV meningitis can occur
with or without the rash of chickenpox or shingles. There
is usually no reduced conscious level in adults with viral
meningitis. An alteration in conscious level suggests an
alternative diagnosis such as bacterial meningitis, enceph-
alitis, encephalopathy due to infection outside the central
nervous system or other intracranial pathology such as a
subarachnoid haemorrhage or a space occupying lesion.
How should viral meningitis be investigated?
Because the presenting clinical features for bacterial and
viral meningitis are similar,82 the initial investigations are
the same, as described earlier in the investigations section.
430 F. McGill et al.If a viral cause is suspected following CSF examination (see
Table 4) then viral pathogens should be looked for, normally
by CSF PCR. Although a positive PCR may not lead to any
specific antiviral treatment, identifying a viral pathogen al-
lows the patient to be given a diagnosis and antibiotics to
be stopped; it also reduces the number of investigations
performed and the duration of hospital stay.8,258,259
CSF PCR is the gold standard for confirmation of viral
meningitis.246,260 Most laboratories will test for enterovirus,
HSV-1, HSV-2 and VZV. No cause is found in 30e50% of pa-
tients with presumed viral meningitis.18,19,254Other investigations
Unlike in bacterial meningitis the white cell count in the
blood and CRP are often normal in viral meningitis (espe-
cially in herpes meningitis). In enteroviral meningitis, virus
may also be detected by throat swabs, in stool, or skin
vesicles if present.261,262How should viral meningitis be treated?
There are currently no treatments of proven benefit for
most causes of viral meningitis. Some clinicians treat
herpes meningitis with aciclovir or valaciclovir, but to
date, there is no evidence to support this, for either HSV
or VZV. Although in theory these drugs may be beneficial,
there are potential risks from drug side effects and unnec-
essarily prolonged hospitalisation; these risks should be
weighed against the lack of evidence for efficacy. Treat-
ment should be supportive with analgesia and fluids if
necessary. If antibiotics have been commenced they should
be stopped once a viral diagnosis is made, and priority given
to expediting discharge from hospital. If there are any
suggestions of encephalitis such as changes in personality,
behaviour or cognition or altered conscious level intrave-
nous aciclovir should be given for suspected HSV enceph-
alitis, and the British Infection Association/Association of
British Neurologists guidelines on the management of
encephalitis should be followed.64
Some people suffer from recurrent episodes of lympho-
cytic meningitis or, as it is often referred to eponymously,
Mollaret’s meningitis.263 Large granular plasma cells are
considered to be the hallmark of Mollaret’s meningitis,
but in reality, these are rarely seen. Recurrent lymphocytic
meningitis is most often caused by HSV-2,264e266 although
there have been case reports of other viruses.267e270 The
episodes of meningitis can be months to years apart but
there is normally complete recovery in between episodes.
Despite oral valaciclovir reducing transmission of genital
HSV-2 between discordant couples271 and reducing recur-
rences in genital disease272 it did not reduce recurrent
HSV-2 meningitis in a placebo-controlled trial; indeed pa-
tients who received valaciclovir tended to have a greater
rate of relapse once the trial stopped.273 The lack of effi-
cacy was postulated by the authors to be due to low levels
of drug in the CSF (although aciclovir concentration was not
measured in this study). Potentially a higher dose may give
better outcomes but no study has evaluated this as yet. Pa-
tients with recurrent episodes of confirmed or probableviral meningitis should be assessed by an infection or neuro-
logical specialist.
When should these guidelines be reviewed?
These guidelines and the relevant literature will be re-
viewed at 5 years after publication. If anything significant is
published in the interim there will be an interim guideline
statement issued.
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